Dore GJ; Dore G; Lloyd AROLA, (eds.), 2009, Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn
Hajarizadeh B; Martinello M; Dore G, 2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer, https://doi.org/10.1007/978-3-030-64649-3_11
Dore GJ; Martinello M, 2020, 'Global elimination of hepatitis C virus by 2030: the optimistic view', in , Wiley, pp. 238 - 243, http://dx.doi.org/10.1002/9781119533481.ch40
Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
Martinello MK; Grebely J; Dore G, 2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press, pp. 4409 - 4431, http://dx.doi.org/10.1201/9781315152110
Thein H-H; Dore GJ, 2010, 'Cognitive Function, Mood and Health-Related Quality of Life in Hepatitis C Virus-Infected Individuals', in Handbook of Disease Burdens and Quality of Life Measures, Springer New York, pp. 3299 - 3326, http://dx.doi.org/10.1007/978-0-387-78665-0_191
Dore GJ; Temple-Smith M; Lloyd AROLA, 2009, 'Future challenges for hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 433 - 452, http://www.ipcommunications.com.au/
Grebely J; Dore GJ, 2009, 'Acute hepatitis C infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 230 - 253
Loveday S; Dore GJ, 2009, 'Improving quality of life for people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 172 - 180
Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 308 - 329
Dore GJ, 2009, 'Therapy decision-making for people with chronic hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 181 - 191
Boesecke C; Dore GJ; Cooper DA, 2009, 'AIDS: Clinical Manifestations', in Encyclopedia of Life Sciences (eLS), edn. 3rd, John Wiley & Sons, Ltd., Chichester, pp. 1 - 10, http://dx.doi.org/10.1002/9780470015902.a0002237.pub2
Thein HH; Dore GJ, 2009, 'Natural history of hepatitis C virus infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 76 - 89
Dore GJ, 2009, 'Initial assessment and clinical monitoring of people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 156 - 169
Nguyen VT; Dore GJ, 2008, 'Prevalence and epidemiology of hepatitis B', in Matthews G; Robotin M (ed.), B positive: All you wanted to know about hepatitis B: A guide for primary care providers, edn. 1st, Australasian Society for HIV Medicine (ASHM), Darlinghurst, Australia, pp. 13 - 23, http://www.ashm.org.au/images/publications/monographs/b%20positive/b_positive-all_you_wanted_to_know.pdf
Dore GJ; Cooper DA, 2003, '
Dore GJ, 2001, 'Theapy decision-making for people with chronic hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, edn. 1, IP Communications, Melbourne, pp. 172 - 182
Dore GJ, 2001, 'Natural history of hepatitis C infection', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, edn. 1, IP Communications, Melbourne, pp. 82 - 100
Dore GJ, 2001, 'Initial assessment and clinical monitoring of people with hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, edn. 1, IP Communications, Melbourne, pp. 129 - 139
Correll PK; MacDonald MA; Dore GJ, 2000, 'Hepatitis C infection in indigenous communities in Australia', in Hepatitis C: Informing Australia`s Response, edn. Original, Commonwealth Department of Health and Aged Care, Canberra, pp. 47 - 60
Dore GJ, 2000, 'Natural history of hepatitis C virus infection', in Hepatitis C: Informing Australia`s Response, edn. Original, Commonwealth Department of Health and Aged Care, Canberra, pp. 95 - 118
MacDonald MA; Correll PK; Dore GJ, 2000, 'Occupational exposure to hepatitis C in health care settings', in Hepatitis C: Informing Australia`s Response, edn. Original, Commonwealth Department of Health and Aged Care, Canberra, pp. 119 - 135
Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J, 2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, vol. 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876
Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J, 2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.', Viruses, vol. 14, http://dx.doi.org/10.3390/v14112463
Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P, 2022, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: a modelling study.', Liver Int, http://dx.doi.org/10.1111/liv.15469
Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ, 2022, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection.', J Viral Hepat, http://dx.doi.org/10.1111/jvh.13761
Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Bull RA; Martinello M; Lloyd AR; Kaldor J; Dore G; Sorrell T; Rawlinson W; Dwyer D; Post JJ; Hudson B; Bartlett A; Lemberg D; Sasson SC; Di Girolamo N; Bull RA; Martinello M; Byrne M; Hammoud M; Lloyd AR; Sultan R; Post JJ; Mina M; Hudson B; Gilroy N; Rawlinson W; Konecny P; Martinello M; Bartlett A; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, vol. 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272
Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, vol. 4, pp. 100552 - 100552, http://dx.doi.org/10.1016/j.jhepr.2022.100552
Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA, 2022, 'Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review', Clinical Pharmacokinetics, vol. 61, pp. 1331 - 1343, http://dx.doi.org/10.1007/s40262-022-01170-x
Catlett B; Hajarizadeh B; Cunningham E; Wolfson-Stofko B; Wheeler A; Khandaker-Hussain B; Feld JJ; Martró E; Chevaliez S; Pawlotsky JM; Bharat C; Cunningham PH; Dore GJ; Applegate T; Grebely J, 2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', The Journal of infectious diseases, vol. 226, pp. 1005 - 1021, http://dx.doi.org/10.1093/infdis/jiac049
Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2022, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia.', J Hepatol, http://dx.doi.org/10.1016/j.jhep.2022.09.011
Grebely J; Dore GJ; Altice FL; Conway B; Litwin AH; Norton BL; Dalgard O; Gane EJ; Shibolet O; Nahass R; Luetkemeyer AF; Peng CY; Iser D; Gendrano IN; Kelly MM; Hwang P; Asante-Appiah E; Haber BA; Barr E; Robertson MN; Platt H, 2022, 'Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study', Annals of Internal Medicine, vol. 175, pp. 1221 - 1229, http://dx.doi.org/10.7326/M21-4119
Bartlett SR; Verich A; Carson J; Hosseini-Hooshyar S; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Martinez M; Marks P; Dore GJ; Matthews GV; Applegate T; Martinello M, 2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, vol. 5, http://dx.doi.org/10.1002/hsr2.719
Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Matthews GV; Dore GJ; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Stewart J; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, vol. 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, vol. 106, pp. 103746, http://dx.doi.org/10.1016/j.drugpo.2022.103746
Catlett B; Starr M; Machalek DA; Danwilai T; Palmer M; Kelly A; Kaldor J; Dore GJ; Darley D; Matthews G; Cunningham PH, 2022, 'Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection: SARS-CoV-2 detection from dried blood spots', Journal of Clinical Virology Plus, vol. 2, http://dx.doi.org/10.1016/j.jcvp.2022.100093
Wheeler A; Valerio H; Cunningham EB; Martinello M; Barocas JA; Colledge-Frisby S; Treloar C; Amin J; Henderson C; Read P; Matthews GV; Dunlop AJ; Gorton C; Hayllar J; Alavi M; Murray C; Marks P; Silk D; Degenhardt L; Dore GJ; Grebely J, 2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, vol. 237, pp. 109543, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
Lockart I; Yeo MGH; Hajarizadeh B; Dore G; Danta M; Abe K; Carrat F; Lusivika-Nzinga C; Degasperi E; Di Marco V; Hou J; Howell J; Janjua NZ; Wong S; Kumada T; Lleo A; Persico M; Lok AS; Wei L; Yang M; Nabatchikova E; Nguyen MH; Antonio Pineda J; Reig M; Shiha G; Yu ML; Tsai PC, 2022, 'HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis', Hepatology, vol. 76, pp. 139 - 154, http://dx.doi.org/10.1002/hep.32341
Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', JOURNAL OF HEPATOLOGY, vol. 77, pp. S565 - S565, http://dx.doi.org/10.1093/cid/ciac246
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, vol. 14, http://dx.doi.org/10.3390/v14071496
Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J, 2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, vol. 14, http://dx.doi.org/10.3390/v14071555
Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Christmass M; Cock V; Burns C; Henderson C; Wiseman V; Dore GJ; Grebely J, 2022, 'Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment', Drug and Alcohol Dependence, vol. 235, pp. 109438, http://dx.doi.org/10.1016/j.drugalcdep.2022.109438
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV, 2022, 'Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression', The Lancet HIV, vol. 9, pp. e414 - e427, http://dx.doi.org/10.1016/S2352-3018(22)00077-7
Lazarus JV; Picchio CA; Byrne CJ; Crespo J; Colombo M; Cooke GS; Dore GJ; Grebely J; Ward JW; Dillon JF, 2022, 'A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination', Seminars in Liver Disease, vol. 42, pp. 159 - 172, http://dx.doi.org/10.1055/a-1777-6112
Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F; Martinello M; Matthews G; Fernando FF; Esteban JI; Müllhaupt B; Wiesch JSZ; Buggisch P; Neumann-Haefelin C; Berg T; Berg CP; Schattenberg JM; Moreno C; Stauber R; Lloyd A; Dore G; Applegate T; Ignacio J; Garcia-Cehic D; Gregori J; Rodriguez-Frias F; Rando A; Gozlan Y; Angelico M; Andreoni M; Babudieri S; Bertoli A; Cento V; Coppola N; Craxì A; Paolucci S; Parruti G; Pasquazzi C; Perno CF; Teti E; Vironet C; Lannergård A; Duberg AS; Aleman S; Gutteberg T; Soulier A; Gourgeon A; Chevaliez S; Pol S; Carrat F; Salmon D; Kaiser R; Knopes E; Gomes P; de Kneght R; Rijnders B; Poljak M; Lunar M; Usubillaga R; Seguin_Devaux C; Tay E; Wilson C; Wang DS; George J; Kok J; Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A, 2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, vol. 4, pp. 100462 - 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Valencia BM; Bajis S; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2022, 'Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, vol. 7, pp. 426 - 445, http://dx.doi.org/10.1016/S2468-1253(21)00471-4
Hosseini-Hooshyar S; Alavi M; Martinello M; Valerio H; Tillakeratne S; Matthews GV; Dore GJ, 2022, 'Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study', Journal of Viral Hepatitis, vol. 29, pp. 271 - 279, http://dx.doi.org/10.1111/jvh.13658
Yee J; Carson JM; Hajarizadeh B; Hanson J; O’Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV; Hanson J; Read P; Carson J; Byrne M; Post J; Doyle J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Read P; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Davies J; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, vol. 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L, 2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, vol. 100, pp. 103492 - 103492, http://dx.doi.org/10.1016/j.drugpo.2021.103492
Chidwick K; Myton R; Rodgers A; Jun M; Dartnell J; Balcomb A; Dore G, 2022, 'A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial)', Journal of Viral Hepatitis, vol. 29, pp. 135 - 146, http://dx.doi.org/10.1111/jvh.13629
Phetsouphanh C; Darley DR; Wilson DB; Howe A; Munier CML; Patel SK; Juno JA; Burrell LM; Kent SJ; Dore GJ; Kelleher AD; Matthews GV, 2022, 'Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection', Nature Immunology, vol. 23, pp. 210 - 216, http://dx.doi.org/10.1038/s41590-021-01113-x
Oliu-Barton M; Pradelski BSR; Algan Y; Baker MG; Binagwaho A; Dore GJ; El-Mohandes A; Fontanet A; Peichl A; Priesemann V; Wolff GB; Yamey G; Lazarus JV, 2022, 'Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines', The Lancet Global Health, vol. 10, pp. e142 - e147, http://dx.doi.org/10.1016/S2214-109X(21)00494-0
Blach S; Terrault NA; Tacke F; Gamkrelidze I; Craxi A; Tanaka J; Waked I; Dore GJ; Abbas Z; Abdallah AR; Abdulla M; Aghemo A; Aho I; Akarca US; Alalwan AM; Alanko Blomé M; Al-Busafi SA; Aleman S; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Al Serkal YM; Altraif IH; Anand AC; Anderson M; Andersson MI; Athanasakis K; Baatarkhuu O; Bakieva SR; Ben-Ari Z; Bessone F; Biondi MJ; Bizri ARN; Brandão-Mello CE; Brigida K; Brown KA; Brown, RS; Bruggmann P; Brunetto MR; Busschots D; Buti M; Butsashvili M; Cabezas J; Chae C; Chaloska Ivanova V; Chan HLY; Cheinquer H; Cheng KJ; Cheon ME; Chien CH; Chien RN; Choudhuri G; Christensen PB; Chuang WL; Chulanov V; Cisneros LE; Coco B; Contreras FA; Cornberg M; Cramp ME; Crespo J; Cui F; Cunningham CW; Dagher Abou L; Dalgard O; Dao DY; De Ledinghen V; Derbala MF; Deuba K; Dhindsa K; Djauzi S; Drazilova S; Duberg AS; Elbadri M; El-Sayed MH; Esmat G; Estes C; Ezzat S; Färkkilä MA; Ferradini L; Ferraz MLG; Ferreira PRA; Filipec Kanizaj T; Flisiak R; Frankova S; Fung J; Gamkrelidze A; Gane E; Garcia V; García-Samaniego J; Gemilyan M; Genov J; Gheorghe LS; Gholam PM; Goldis A; Gottfredsson M; Gray RT; Grebely J; Gschwantler M, 2022, 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study', The Lancet Gastroenterology and Hepatology, http://dx.doi.org/10.1016/S2468-1253(21)00472-6
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; ETHOS Engage Study Group , 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, vol. 105, pp. 103706, http://dx.doi.org/10.1016/j.drugpo.2022.103706
Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)', Harm Reduction Journal, vol. 18, pp. 46, http://dx.doi.org/10.1186/s12954-021-00494-4
Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ, 2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, vol. 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526
Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2021, 'Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel', International Journal of Drug Policy, vol. 98, pp. 103379, http://dx.doi.org/10.1016/j.drugpo.2021.103379
Lockart I; Hajarizadeh B; Buckley N; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2021, 'All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy', Journal of Gastroenterology and Hepatology (Australia), vol. 36, pp. 3515 - 3523, http://dx.doi.org/10.1111/jgh.15687
Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; Macquillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ, 2021, 'Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics', Clinical Infectious Diseases, vol. 73, pp. E3288 - E3295, http://dx.doi.org/10.1093/cid/ciaa1318
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P, 2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, vol. 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002
Dore G; Levy M, 2021, 'Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics', Clinical Infectious Diseases, http://dx.doi.org/10.1093/cid/ciaa1318
Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B, 2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, vol. 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204
Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the ‘Surveillance and Treatment of Prisoners with Hepatitis C’ project (SToP-C)', Addiction, vol. 116, pp. 2761 - 2769, http://dx.doi.org/10.1111/add.15477
Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; Marks P; Amjad S; Tu E; Tamaddoni M; Thurnheer MC; Gilleece Y; Fraser C; Moriggia A; Lutz T; Moon J; Read P; Kim AY; Ustianowski A; Cordes C; Sasadeusz J; Hull M; Braun D, 2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, vol. 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056
Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B, 2021, 'Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis', Journal of Viral Hepatitis, vol. 28, pp. 1340 - 1354, http://dx.doi.org/10.1111/jvh.13574
Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV, 2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, vol. 96, pp. 103422, http://dx.doi.org/10.1016/j.drugpo.2021.103422
Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J, 2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, vol. 96, pp. 103421, http://dx.doi.org/10.1016/j.drugpo.2021.103421
Darley DR; Dore GJ; Byrne AL; Plit ML; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of sars-cov-2 at 8 months in a prospective cohort', ERJ Open Research, vol. 7, pp. 00384 - 2021, http://dx.doi.org/10.1183/23120541.00384-2021
Stephens J; Bradley C; Elliott S; Dore G; Grebely J; Alavi M; Kennedy B; Tong S; Ward J, 2021, 'Hepatitis C in South Australia and Northern Territory: a population-based linkage study', INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, vol. 50, http://dx.doi.org/10.23889/ijpds.v5i5.1545
Stephens J; Bradley C; Elliott S; Dore G; Grebely J; Alavi M; Kennedy B; Tong S; Ward J, 2021, '843Hepatitis C in South Australia and Northern Territory: a population-based linkage study', International Journal of Epidemiology, vol. 50, http://dx.doi.org/10.1093/ije/dyab168.636
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT, 2021, 'Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications', PLoS ONE, vol. 16, pp. e0257369, http://dx.doi.org/10.1371/journal.pone.0257369
Palmer AY; Wilkinson A; Aitken C; Dietze P; Dore GJ; Maher L; Sacks-Davis R; Stoove M; Wilson D; Hellard M; Scott N, 2021, 'Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 36, pp. 2270 - 2274, http://dx.doi.org/10.1111/jgh.15485
Abid A; Uddin M; Muhammad T; Awan S; Applegate T; Dore GJ; Cloherty G; Hamid S, 2021, 'Evaluation of hepatitis C virus core antigen assay in a resource-limited setting in Pakistan', Diagnostics, vol. 11, pp. 1354 - 1354, http://dx.doi.org/10.3390/diagnostics11081354
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J, 2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, vol. 73, pp. E69 - E78, http://dx.doi.org/10.1093/cid/ciaa571
Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B, 2021, 'Association between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection among People Who Inject Drugs: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, vol. 73, pp. E107 - E118, http://dx.doi.org/10.1093/cid/ciaa612
Alavi M; Moghanibashi-Mansourieh A; Radfar SR; Alizadeh S; Bahramabadian F; Esmizade S; Dore GJ; Sedeh FB; Deilamizade A, 2021, 'Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs', International Journal of Drug Policy, vol. 93, pp. 102908, http://dx.doi.org/10.1016/j.drugpo.2020.102908
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Loveday S; Tamaddoni M; Obeid S; Estivill Mercade G; Martinez M; Donnelly R; Bowman J; Trevethan L; Lagios K; Murrell T; Bath N; Tawil V; Stevens A; Topp L; Churchill A; Pinnock K; Drew S; Harrod M; Smith A; Williams R; Cooper B; Somes K; Burns C; Kaur A; Lobo C; Conroy K; McCredie L; Café C; Anlezark J; Rawlinson W; Yeang M; Wynn M; Willenborg C, 2021, 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study', The Lancet Gastroenterology and Hepatology, vol. 6, pp. 533 - 546, http://dx.doi.org/10.1016/S2468-1253(21)00077-7
Liu B; Jayasundara D; Pye V; Dobbins T; Dore GJ; Matthews G; Kaldor J; Spokes P, 2021, 'Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia', The Lancet Regional Health - Western Pacific, vol. 12, pp. 100193, http://dx.doi.org/10.1016/j.lanwpc.2021.100193
Busingye D; Chidwick K; Simpson V; Dartnell J; J Dore G; Balcomb A; Blogg S, 2021, 'The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian Pharmaceutical Benefits Scheme', JGH Open, vol. 5, pp. 813 - 819, http://dx.doi.org/10.1002/jgh3.12593
Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Fichter C; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffmann M; Pöhlman S; Mazigi O; Christ D; Rockett RJ; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2021, 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants', PLoS Medicine, vol. 18, http://dx.doi.org/10.1371/journal.pmed.1003656
Dore G, 2021, 'Australian COVID-19 response: Lessons and future directions', Journal and Proceedings of the Royal Society of New South Wales, vol. 154, pp. 78 - 84
Marriott D; Beresford R; Mirdad F; Stark D; Glanville A; Chapman S; Harkness J; Dore GJ; Andresen D; Matthews GV, 2021, 'Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW', Clinical Infectious Diseases, vol. 72, pp. E649 - E651, http://dx.doi.org/10.1093/cid/ciaa1256
Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C, 2021, 'The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting', Addiction, vol. 116, pp. 1162 - 1171, http://dx.doi.org/10.1111/add.15277
Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2021, 'Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival', Journal of Viral Hepatitis, vol. 28, pp. 710 - 718, http://dx.doi.org/10.1111/jvh.13475
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, vol. 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253
Darley D; Matthews G; Dore G; Wilhelm K; Plit M; Stone E; Byrne A; Tonga K; Andresen D; Kelleher A; Cysique L; Cunningham P; Brew B, 2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.50963
Dore GJ; Cowie B, 2021, 'Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive', Clinical Infectious Diseases, vol. 72, pp. 753 - 754, http://dx.doi.org/10.1093/cid/ciaa138
Catlett B; Bajis S; Starr M; Dore GJ; Hajarizadeh B; Cunningham PH; Applegate TL; Grebely J, 2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, vol. 223, pp. 818 - 826, http://dx.doi.org/10.1093/infdis/jiaa442
Applegate T; Bajis S; Catlett B; Cunningham P; Dore G; Grebely J; Hajarizadeh B, 2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, http://dx.doi.org/10.1093/infdis/jiaa442
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, vol. 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038
Dore GJ; Bajis S, 2021, 'Hepatitis C virus elimination: laying the foundation for achieving 2030 targets', Nature Reviews Gastroenterology and Hepatology, vol. 18, pp. 91 - 92, http://dx.doi.org/10.1038/s41575-020-00392-3
Dore GJ; Bajis S, 2021, 'Author Correction: Hepatitis C virus elimination: laying the foundation for achieving 2030 targets (Nature Reviews Gastroenterology & Hepatology, (2021), 18, 2, (91-92), 10.1038/s41575-020-00392-3)', Nature Reviews Gastroenterology and Hepatology, vol. 18, pp. 143, http://dx.doi.org/10.1038/s41575-020-00407-z
Hamid S; Abid A; Dore GJ, 2021, 'Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas', The Lancet Gastroenterology and Hepatology, vol. 6, pp. 89 - 90, http://dx.doi.org/10.1016/S2468-1253(20)30371-X
Prince DS; Pipicella JL; Fraser M; Alvaro F; Maley M; Foo H; Middleton PMC; Davison SA; Dore GJ; McCaughan GW; Levy MT, 2021, 'Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or ‘re-diagnose’ infections is effective in Australia', Journal of Viral Hepatitis, vol. 28, pp. 121 - 128, http://dx.doi.org/10.1111/jvh.13393
Jin F; Dore GJ; Matthews G; Luhmann N; Macdonald V; Bajis S; Baggaley R; Mathers B; Verster A; Grulich AE, 2021, 'Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, vol. 6, pp. 39 - 56, http://dx.doi.org/10.1016/S2468-1253(20)30303-4
Dore GJ, 2021, 'Elimination of hepatitis c in australia by 2030: A decade and counting', Australian Prescriber, vol. 44, pp. 36 - 37, http://dx.doi.org/10.18773/austprescr.2021.003
Darley DR; Dore GJ; Byrne A; Plit M; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort', , http://dx.doi.org/10.1101/2021.03.29.21254211
Phetsouphanh C; Darley D; Wilson D; Howe A; Ling Munier M; Patel S; Juno J; Burrell L; Kent S; Dore G; Kelleher A; Matthews G, 2021, 'Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection', , http://dx.doi.org/10.1101/2021.06.01.21257759
Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; Pöhlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2020, 'SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants', , http://dx.doi.org/10.1101/2020.12.19.20248567
Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ, 2020, 'Novel hepatitic C virus (HCV) diagnosis and treatment delivery systems: Facilitating HCV elimination by thinking outside the clinic', Journal of Infectious Diseases, vol. 222, pp. S758 - S772, http://dx.doi.org/10.1093/infdis/jiaa366
Trooskin SB; Dore G; Kostman J, 2020, 'We must do better: Addressing HCV treatment barriers in persons who inject drugs in the United States', Journal of Infectious Diseases, vol. 222, pp. S773 - S781, http://dx.doi.org/10.1093/infdis/jiaa574
Dore GJ; Danta M; Matthews GV, 2020, 'Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding', The Lancet Gastroenterology and Hepatology, vol. 5, pp. 1028 - 1029, http://dx.doi.org/10.1016/S2468-1253(20)30270-3
Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, vol. 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089
Dore GJ; Valerio H; Grebely J, 2020, 'Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C', Liver International, vol. 40, pp. 2353 - 2355, http://dx.doi.org/10.1111/liv.14661
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, vol. 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L, 2020, 'Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy', International Journal of Drug Policy, vol. 83, http://dx.doi.org/10.1016/j.drugpo.2020.102837
Dore GJ; Trooskin S, 2020, 'People with hepatitis C who inject drugs — Underserved, not undeserving', New England Journal of Medicine, vol. 383, pp. 608 - 611, http://dx.doi.org/10.1056/NEJMp2002126
Dore G; Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Mcmanus H; Butler T; Vickerman P; Martin N; Mchutchison J; Brainard D; Treloar C; Lloyd A, 2020, 'Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study', JOURNAL OF HEPATOLOGY, vol. 73, pp. S127 - S127, http://dx.doi.org/10.1016/s0168-8278(20)30769-8
Valerio H; Alavi M; Matthews G; Law M; McManus H; Amin J; Janjua N; Krajden M; Tillakeratne S; Gleeson V; George J; Degenhardt L; Grebely J; Dore G, 2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, vol. 73, pp. S807 - S808, http://dx.doi.org/10.1016/s0168-8278(20)32060-2
Dalgard O; Litwin A; Dore G; Shibolet O; Grebely J; Nahass R; Altice F; Conway B; Gane E; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Kelly MM; Haber B; Platt HL; Puenpatom A, 2020, 'Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR', JOURNAL OF HEPATOLOGY, vol. 73, pp. S356 - S356, http://dx.doi.org/10.1016/s0168-8278(20)31208-3
Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M, 2020, 'Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study', BMJ Open, vol. 10, pp. e034389, http://dx.doi.org/10.1136/bmjopen-2019-034389
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, vol. 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
Grebely J; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D; Dore GJ; Applegate TL, 2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, vol. 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, vol. 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, vol. 3, pp. e151, http://dx.doi.org/10.1002/hsr2.151
Douglas MW; Tay ESE; Wang DS; Ong ATL; Wilson C; Phu A; Kok J; Dwyer DE; Bull RA; Lloyd AR; Applegate TL; Dore GJ; Howe AY; Harrigan R; George J, 2020, 'Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance', Hepatology Communications, vol. 4, pp. 904 - 915, http://dx.doi.org/10.1002/hep4.1496
Martinello M; Bajis S; Dore GJ, 2020, 'Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation', Gastroenterology Clinics of North America, vol. 49, pp. 253 - 277, http://dx.doi.org/10.1016/j.gtc.2020.01.005
Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, vol. 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101
Dore GJ; Matthews GV, 2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, vol. 17, pp. 321 - 322, http://dx.doi.org/10.1038/s41575-020-0306-8
Martinello M; Hajarizadeh B; Dore GJ, 2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, vol. 212, pp. 362 - 363, http://dx.doi.org/10.5694/mja2.50584
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, vol. 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, vol. 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, vol. 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C, 2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, vol. 77, pp. 102693 - 102693, http://dx.doi.org/10.1016/j.drugpo.2020.102693
Dore GJ; Martinello M; Alavi M; Grebely J, 2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, vol. 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x
Boettiger DC; Salazar-Vizcaya L; Dore GJ; Gray RT; Law MG; Callander D; Lea T; Rauch A; Matthews GV, 2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, vol. 70, pp. 106 - 113, http://dx.doi.org/10.1093/cid/ciz164
Geddes L; Iversen J; Wand H; Esmaeili A; Tsui J; Hellard M; Dore G; Grebely J; Dietze P; Bruneau J; Prins M; Morris MD; Shoukry NH; Lloyd AR; Kim AY; Lauer G; Cox AL; Page K; Maher L, 2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, vol. 70, pp. 123 - 131, http://dx.doi.org/10.1093/cid/ciz162
Marshall AD; Grebely J; Dore GJ; Treloar C, 2020, 'Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience', Drug and Alcohol Dependence, vol. 206, pp. 107705, http://dx.doi.org/10.1016/j.drugalcdep.2019.107705
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ, 2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, vol. 51, pp. 34 - 52, http://dx.doi.org/10.1111/apt.15598
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, vol. 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562
Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Durán R; Fischer J; Nattermann J; D’Ambrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, vol. 9, http://dx.doi.org/10.1038/s41598-018-35736-2
Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, vol. 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196
Alavi M; Law MG; Dore GJ, 2019, 'Reply to: “Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis”', Journal of Hepatology, vol. 71, pp. 1254 - 1255, http://dx.doi.org/10.1016/j.jhep.2019.07.011
Safreed-Harmon K; Blach S; Aleman S; Bollerup S; Cooke G; Dalgard O; Dillon JF; Dore GJ; Duberg AS; Grebely J; Boe Kielland K; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus JV, 2019, 'The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination', Clinical Infectious Diseases, vol. 69, pp. 2218 - 2227, http://dx.doi.org/10.1093/cid/ciz714
Lafferty L; Rance J; Treloar C, 2019, '‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures', Drugs: Education, Prevention and Policy, vol. 26, pp. 502 - 507, http://dx.doi.org/10.1080/09687637.2018.1494135
Read P; Gilliver R; Kearley J; Lothian R; Cunningham EB; Chronister KJ; Dore GJ, 2019, 'Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection', Journal of Viral Hepatitis, vol. 26, pp. 1301 - 1310, http://dx.doi.org/10.1111/jvh.13175
Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, vol. 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002
Dillon JF; Miller MH; Robinson EM; Hapca A; Rezaeihemami M; Weatherburn C; McIntyre PG; Bartlett B; Donnan PT; Boyd KA; Dow E, 2019, 'Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care', Journal of Hepatology, vol. 71, pp. 699 - 706, http://dx.doi.org/10.1016/j.jhep.2019.05.033
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, vol. 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, vol. 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014
Abayasingam A; Leung P; Eltahla A; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd A; Rodrigo C, 2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection, Genetics and Evolution, vol. 71, pp. 36 - 41, http://dx.doi.org/10.1016/j.meegid.2019.02.032
Dore GJ, 2019, 'HCV reinfection as a positive indication of high-risk population treatment access', Journal of Viral Hepatitis, vol. 26, pp. 516 - 518, http://dx.doi.org/10.1111/jvh.13092
Rodrigo C; Leung P; Lloyd AR; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Eltahla AA, 2019, 'Genomic variability of within-host hepatitis C variants in acute infection', Journal of Viral Hepatitis, vol. 26, pp. 476 - 484, http://dx.doi.org/10.1111/jvh.13051
Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, vol. 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016
Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ, 2019, 'Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy', International Journal of Drug Policy, vol. 66, pp. 73 - 79, http://dx.doi.org/10.1016/j.drugpo.2019.01.011
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, vol. 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3
Dore G; Feld J; Thompson A; Martinello M; Muir A; Agarwal K; Mullhaupt B; Wedemeyer H; Lacombe K; Matthews G; Schultz M; Mercade GE; Kho D; Filep E; Petoumenos K; Marks P; Tatsch F; dos Santos AGP; Gane E, 2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, vol. 70, pp. E110 - E110, http://dx.doi.org/10.1016/S0618-8278(19)30196-3
Safreed-Harmon K; Blach S; Aleman S; Kielland KB; Bollerup S; Cooke G; Dalgard O; Dillon J; Dore G; Du Berg A-S; Grebely J; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus J, 2019, 'The consensus hepatitis C cascade of care: Methodology and initial findings from three countries', JOURNAL OF HEPATOLOGY, vol. 70, pp. E333 - E334, http://dx.doi.org/10.1016/S0618-8278(19)30651-6
Cooke GS; Andrieux-Meyer I; Applegate TL; Atun R; Burry JR; Cheinquer H; Dusheiko G; Feld JJ; Gore C; Griswold MG; Hamid S; Hellard ME; Hou JL; Howell J; Jia J; Kravchenko N; Lazarus JV; Lemoine M; Lesi OA; Maistat L; McMahon BJ; Razavi H; Roberts TR; Simmons B; Sonderup MW; Spearman CW; Taylor BE; Thomas DL; Waked I; Ward JW; Wiktor SZ; Abdo A; Aggarwal R; Aghemo A; Al-Judaibi B; Al Mahtab M; Altaf A; Ameen Z; Asselah T; Baatarkkhuu O; Barber E; Barnes E; Boulet P; Burrows L; Butsashvili M; Chan E; Chow C; Cowie B; Cunningham C; de Araujo A; Diap G; Dore G; Doyle J; Elsayed M; Fajardo E; Gane E; Getehun A; Goldberg D; Got T; Hickman M; Hill A; Hutchinson S; Jones C; Kamili S; Khan A; Lee A; Lee TY; Malani J; Morris TM; Nayagam S; Njouom R; Ocama P; Pedrana A; Peeling R; Reddy A; Roberts T; Sacks J; Sarin S; Shimakawa Y; Silva M; Skala P; Taylor-Robinson S; Thompson A; Thursz M; Tonganibeia A; Wallace J; Ward J; Wolff F; Vickerman P; Yau J, 2019, 'Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission', The Lancet Gastroenterology and Hepatology, vol. 4, pp. 135 - 184, http://dx.doi.org/10.1016/S2468-1253(18)30270-X
Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, vol. 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222
Grebely J; Larney S; Peacock A; Colledge S; Leung J; Hickman M; Vickerman P; Blach S; Cunningham EB; Dumchev K; Lynskey M; Stone J; Trickey A; Razavi H; Mattick RP; Farrell M; Dore GJ; Degenhardt L, 2019, 'Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs', Addiction, vol. 114, pp. 150 - 166, http://dx.doi.org/10.1111/add.14393
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, vol. 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L, 2019, 'Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia', Journal of Hepatology, vol. 70, pp. 33 - 39, http://dx.doi.org/10.1016/j.jhep.2018.09.030
Foster GR; Dore GJ; Wang S; Grebely J; Sherman KE; Baumgarten A; Conway B; Jackson D; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar H; Asatryan A; Hu Y; Mensa FJ, 2019, 'Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies', Drug and Alcohol Dependence, vol. 194, pp. 487 - 494, http://dx.doi.org/10.1016/j.drugalcdep.2018.11.007
Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthews G, 2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, vol. 70, pp. e734 - e734, http://dx.doi.org/10.1016/s0618-8278(19)31468-9
Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, vol. 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, vol. 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C, 2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, vol. 25, pp. 1526 - 1532, http://dx.doi.org/10.1111/jvh.12987
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, vol. 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004
Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, vol. 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013
Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J, 2018, 'The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat', Journal of Hepatology, vol. 69, pp. 1188 - 1196, http://dx.doi.org/10.1016/j.jhep.2018.06.016
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, vol. 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011
Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2
Grebely J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster GR; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Schnell G; Alami NN; Zhang Z; Dumas E; Dore GJ, 2018, 'Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofy248
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, vol. 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, vol. 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofy033
Bartlett SR; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Dore GJ; Russell DB, 2018, 'Demonstration of near-elimination of Hepatitis C virus among a prison population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project', Clinical Infectious Diseases, vol. 67, pp. 460 - 463, http://dx.doi.org/10.1093/cid/ciy210
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, vol. 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, vol. 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852
Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, vol. 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003
Dore GJ; Hajarizadeh B, 2018, 'Elimination of Hepatitis C Virus in Australia: Laying the Foundation', Infectious Disease Clinics of North America, vol. 32, pp. 269 - 279, http://dx.doi.org/10.1016/j.idc.2018.02.006
Dore G; Hoy J; Phanuphak P; Levy J; Lewin SR, 2018, 'Professor David Cooper OBITUARY', AIDS, vol. 32, pp. 1205 - 1206, http://dx.doi.org/10.1097/QAD.0000000000001840
Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, vol. 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114
Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, vol. 18, http://dx.doi.org/10.1186/s12879-018-3110-0
Alavi M; Law MG; Dore GJ, 2018, 'Reply to: “‘Who killed JR’: Chronic hepatitis C or alcohol use disorders?”', Journal of Hepatology, vol. 68, pp. 1099 - 1100, http://dx.doi.org/10.1016/j.jhep.2017.12.021
Dore GJ, 2018, 'Striving for hepatitis C virus elimination or control?', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 295 - 297, http://dx.doi.org/10.1016/S2468-1253(18)30080-3
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, vol. 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837
Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, vol. 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013
Waziry R; Amin J; Law M; Dore GJ, 2018, 'Reply to: “Direct antiviral agents and risk of HCC: Waiting for Godot”', Journal of Hepatology, vol. 68, pp. 616 - 617, http://dx.doi.org/10.1016/j.jhep.2017.10.002
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, vol. 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1
Waziry R; Gomaa A; Waked I; Dore GJ, 2018, 'Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era', Arab Journal of Gastroenterology, vol. 19, pp. 26 - 32, http://dx.doi.org/10.1016/j.ajg.2018.02.004
Marshall AD; Treloar C; Dore GJ; Grebely J, 2018, 'A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY', Journal of the Canadian Association of Gastroenterology, vol. 1, pp. 419 - 419, http://dx.doi.org/10.1093/jcag/gwy008.240
Conway B; Dore GJ; Altice F; Litwin A; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C; Gendrano I; Huang H; Chen E; Nguyen B; Wahl J; Barr E; Robertson M; Platt H, 2018, 'A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)', Journal of the Canadian Association of Gastroenterology, vol. 1, pp. 299 - 300, http://dx.doi.org/10.1093/jcag/gwy008.173
Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, vol. 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005
Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorienė L; Jarcuska P; Kåberg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Matičič M; Norris S; Ólafsson S; Øvrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2018, 'Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 125 - 133, http://dx.doi.org/10.1016/S2468-1253(17)30284-4
Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Mir HM; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourlière M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofy001
Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ, 2018, 'Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection', New England Journal of Medicine, vol. 378, pp. 354 - 369, http://dx.doi.org/10.1056/NEJMoa1702417
Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, vol. 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919
Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, vol. 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768
Hezode C; Kwo P; Sperl J; Dore G; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', Journal of Hepatology, vol. 68, pp. S264 - S265, http://dx.doi.org/10.1016/s0168-8278(18)30742-6
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, vol. 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025
Boettiger DC; Law MG; Dore GJ; Guy R; Callander D; Donovan B; O'Connor CC; Fairley CK; Hellard M; Matthews G, 2017, 'Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: Analysis of national sentinel surveillance data', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2848-0
Samji H; Yu A; Kuo M; Alavi M; Woods R; Alvarez M; Dore GJ; Tyndall M; Krajden M; Janjua NZ, 2017, 'Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development', Journal of Hepatology, vol. 67, pp. 909 - 917, http://dx.doi.org/10.1016/j.jhep.2017.06.025
Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, vol. 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106
Dore GJ; Hatzakis A; Negro F; Waked I, 2017, 'Estimating HCV disease burden—volume 4 (editorial)', Journal of Viral Hepatitis, vol. 24, pp. 4 - 7, http://dx.doi.org/10.1111/jvh.12763
Larney S; Hickman M; Guy R; Grebely J; Dore GJ; Gray RT; Day CA; Kimber J; Degenhardt L, 2017, 'Estimating the number of people who inject drugs in Australia', BMC Public Health, vol. 17, http://dx.doi.org/10.1186/s12889-017-4785-7
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, vol. 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701
Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L, 2017, 'Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia', International Journal of Drug Policy, vol. 47, pp. 77 - 85, http://dx.doi.org/10.1016/j.drugpo.2017.05.022
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I, 2017, 'Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting', International Journal of Drug Policy, vol. 47, pp. 209 - 215, http://dx.doi.org/10.1016/j.drugpo.2017.05.032
Marshall AD; Grebely J; Dore GJ; Treloar C, 2017, '‘I didn't want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study', International Journal of Drug Policy, vol. 47, pp. 153 - 160, http://dx.doi.org/10.1016/j.drugpo.2017.06.001
Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, vol. 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002
Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ, 2017, 'Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs', International Journal of Drug Policy, vol. 47, pp. 51 - 60, http://dx.doi.org/10.1016/j.drugpo.2017.05.019
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ, 2017, 'Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis', Journal of Hepatology, vol. 67, pp. 263 - 271, http://dx.doi.org/10.1016/j.jhep.2017.03.039
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007
Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR, 2017, 'Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials', Gastroenterology, vol. 153, pp. 113 - 122, http://dx.doi.org/10.1053/j.gastro.2017.03.047
Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4
Dore GJ, 2017, 'Commentary on Gountas et al. (2017): Time to focus on empirical evidence for HCV treatment as prevention', Addiction, vol. 112, pp. 1300 - 1301, http://dx.doi.org/10.1111/add.13796
Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, vol. 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M, 2017, 'NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome', Journal of Hepatology, vol. 66, pp. 910 - 918, http://dx.doi.org/10.1016/j.jhep.2017.01.007
Bartlett SR; Wertheim JO; Bull RA; Matthews GV; Lamoury FMJ; Scheffler K; Hellard M; Maher L; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2017, 'A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies', Journal of Viral Hepatitis, vol. 24, pp. 404 - 411, http://dx.doi.org/10.1111/jvh.12652
Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, vol. 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666
Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Grønbæk H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J; Metwally M; White R; Gallego-Duran R; Leung R; Mahajan N; Bassendine M; Rahme A; Rosso C; Mezzabotta L; Malik B; Matthews G; Asimakopoulos A; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santoro R, 2017, 'IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis', Nature Genetics, vol. 49, pp. 795 - 800, http://dx.doi.org/10.1038/ng.3836
Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA, 2017, 'Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection', Infection, Genetics and Evolution, vol. 49, pp. 88 - 96, http://dx.doi.org/10.1016/j.meegid.2017.01.006
Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K, 2017, 'Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration', Clinical Infectious Diseases, vol. 64, pp. 860 - 869, http://dx.doi.org/10.1093/cid/ciw869
Grebely J; Dore GJ, 2017, 'Treatment of HCV in persons who inject drugs: Treatment as prevention', Clinical Liver Disease, vol. 9, pp. 77 - 80, http://dx.doi.org/10.1002/cld.626
Haber B; Gane E; Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'HEPATITIS C VIRUS (HCV) REINFECTION AND INJECTION RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS ON OPIOID AGONIST THERAPY (OAT): CO-STAR THREE-YEAR FOLLOW-UP STUDY', GASTROENTEROLOGY, vol. 152, pp. S1058 - S1059, http://dx.doi.org/10.1016/S0016-5085(17)33575-8
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M, 2017, 'Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries', The Lancet, vol. 389, pp. 1268 - 1272, http://dx.doi.org/10.1016/S0140-6736(16)32051-7
Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Brandao Mello CE; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen CJ; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; De Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Guimaraes Pessoa M; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui YT; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jarčuška P; Jeruma A; Jonasson JG, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9
Rodrigo C; Eltahla AA; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Lloyd AR, 2017, 'Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study', Journal of Viral Hepatitis, vol. 24, pp. 43 - 52, http://dx.doi.org/10.1111/jvh.12616
Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA, 2017, 'Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents', Journal of Viral Hepatitis, vol. 24, pp. 37 - 42, http://dx.doi.org/10.1111/jvh.12615
Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453
Fortier E; Alavi M; Bruneau J; Micallef M; Perram J; Sockalingam S; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2017, 'Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia', Journal of Addiction Medicine, vol. 11, pp. 10 - 18, http://dx.doi.org/10.1097/ADM.0000000000000261
Sheppard-Law S; Zablotska-Manos I; Kermeen M; Holdaway S; Lee A; Zekry A; Dore GJ; George J; Maher L, 2017, 'Factors associated with HBV virological breakthrough', Antiviral Therapy, vol. 22, pp. 53 - 60, http://dx.doi.org/10.3851/IMP3087
Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB, 2017, 'Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there', Journal of the International AIDS Society, vol. 20, http://dx.doi.org/10.7448/IAS.20.1.22146
Lubel J; Strasser S; Stuart KA; Dore G; Thompson A; Pianko S; Bollipo S; Mitchell JL; Fragomeli V; Jones T; Chivers S; Gow P; Iser D; Levy M; Tse E; Gazzola A; Cheng W; Nazareth S; Galhenage S; Wade A; Weltman M; Wigg A; MacQuillan G; Sasadeusz J; George J; Zekry A; Roberts SK, 2017, 'Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study', Antiviral Therapy, vol. 22, pp. 699 - 710, http://dx.doi.org/10.3851/IMP3168
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, vol. 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073
Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe AYM; Miller V; Ceccherini-Silberstein F; Bull RA; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky JM; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review', Hepatology Communications, vol. 1, pp. 379 - 390, http://dx.doi.org/10.1002/hep4.1050
Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Filep E; Skurowski J; Lin L; Lamoury F; Bartlett S; Applegate T; Hellard M; Matthews GV, 2017, 'O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy', Journal of Virus Eradication, vol. 3, pp. 3 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30890-6
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, vol. 3, pp. 2 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30889-x
Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, vol. 3, pp. 9 - 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7
Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, vol. 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2
Bartlett SR; Applegate T; Jacka B; Lamoury F; Bull R; Danta M; Bradshaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2017, 'P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015', Journal of Virus Eradication, vol. 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30747-0
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, vol. 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5
Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, vol. 3, pp. 13 - 14, http://dx.doi.org/10.1016/s2055-6640(20)30745-7
Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Iser DM; Huang HC; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study', Journal of Virus Eradication, vol. 3, pp. 8 - 8, http://dx.doi.org/10.1016/s2055-6640(20)30904-3
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Virus Eradication, vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30896-7
Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', Journal of Hepatology, vol. 66, pp. S513 - S514, http://dx.doi.org/10.1016/s0168-8278(17)31429-0
Russell DB; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Bartlett S; Dore GJ, 2017, 'O16 A regional prison cleared of hepatitis C in less than 12 months', Journal of Virus Eradication, vol. 3, pp. 6 - 6, http://dx.doi.org/10.1016/s2055-6640(20)30899-2
Dore GJ, 2017, 'O1 Hepatitis C: the treatment landscape in 2017', Journal of Virus Eradication, vol. 3, pp. 1 - 1, http://dx.doi.org/10.1016/s2055-6640(20)30884-0
Chronister KJ; Gilliver R; Kearley J; Lothian R; Dore GJ; Read P, 2017, 'P54 Treatment adherence among people who inject drugs taking directly observed direct acting antiviral therapy at Kirketon Road Centre', Journal of Virus Eradication, vol. 3, pp. 30 - 30, http://dx.doi.org/10.1016/s2055-6640(20)30795-0
Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, vol. 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176
Tsui JI; Mirzazadeh A; Hahn JA; Maher L; Bruneau J; Grebely J; Hellard M; Kim AY; Shoukry NH; Cox AL; Prins M; Dore GJ; Lauer G; Lloyd AR; Page K, 2016, 'The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males', Drug and Alcohol Dependence, vol. 169, pp. 156 - 162, http://dx.doi.org/10.1016/j.drugalcdep.2016.10.024
Keoshkerian E; Hunter M; Cameron B; Nguyen N; Sugden P; Bull R; Zekry A; Maher L; Seddiki N; Zaunders J; Kelleher A; Lloyd AR; Dolan K; Haber P; Rawlinson W; Treloar C; Dore G; Luciani F, 2016, 'Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection', Journal of Viral Hepatitis, vol. 23, pp. 985 - 993, http://dx.doi.org/10.1111/jvh.12576
Asimakopoulos A; Mangia A; Dore GJ; Lloyd AR; George J; Eslam M, 2016, 'Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans', Hepatology, vol. 64, pp. 2264 - 2265, http://dx.doi.org/10.1002/hep.28626
Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, vol. 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844
Dore GJ, 2016, 'Hepatitis C treatment as prevention among HIV-infected men who have sex with men: Feasible?', Hepatology, vol. 64, pp. 1834 - 1836, http://dx.doi.org/10.1002/hep.28784
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, vol. 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010
Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ, 2016, 'Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials', Clinical Infectious Diseases, vol. 63, pp. 1479 - 1481, http://dx.doi.org/10.1093/cid/ciw579
Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials', Clinical Infectious Diseases, vol. 63, pp. 1405 - 1411, http://dx.doi.org/10.1093/cid/ciw580
Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AYM; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL, 2016, 'Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial', Annals of Internal Medicine, vol. 165, pp. 625 - 634, http://dx.doi.org/10.7326/M16-0816
Rodrigo C; Eltahla AA; Bull RA; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Estes C; Razavi H; Lloyd AR; Luciani F, 2016, 'Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia', Journal of Infectious Diseases, vol. 214, pp. 1383 - 1389, http://dx.doi.org/10.1093/infdis/jiw389
Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, vol. 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025
Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; Van Der Poorten D; George J; Eslam M; Gallego-Duran R; Applegate T; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C', Nature Communications, vol. 7, http://dx.doi.org/10.1038/ncomms12757
Grebely J; Litwin A; Dore GJ, 2016, 'Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all', Journal of Viral Hepatitis, vol. 23, pp. 664 - 666, http://dx.doi.org/10.1111/jvh.12550
Chen Yi Mei SLG; Burchell J; Skinner N; Millen R; Matthews G; Hellard M; Dore GJ; Desmond PV; Sundararajan V; Thompson AJ; Visvanathan K; Sasadeusz J, 2016, 'Toll-like receptor expression and signaling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis c virus infection', Journal of Infectious Diseases, vol. 214, pp. 739 - 747, http://dx.doi.org/10.1093/infdis/jiw235
Bradshaw D; Raghwani J; Jacka B; Sacks-Davis R; Lamoury F; Down I; Prestage G; Applegate TL; Hellard M; Sasadeusz J; Dore GJ; Pybus OG; Matthews GV; Danta M, 2016, 'Venue-based networks may underpin HCV transmissions amongst HIV-infected gay and bisexual men', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0162002
Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation', Journal of Hepatology, vol. 65, pp. 17 - 25, http://dx.doi.org/10.1016/j.jhep.2016.02.007
Eslam M; Mangia A; Berg T; Chan HLY; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MAM; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J; White R; Rojas A; Gallego-Duran R; Bassendine M; Wong VWS; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes', Hepatology, vol. 64, pp. 34 - 46, http://dx.doi.org/10.1002/hep.28475
Jacka B; Applegate T; Poon AF; Raghwani J; Harrigan PR; Debeck K; Milloy MJ; Krajden M; Olmstead A; Joy JB; Marshall BDL; Hayashi K; Pybus OG; Lima VD; Magiorkinis G; Montaner J; Lamoury F; Dore GJ; Wood E; Grebely J, 2016, 'Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada', Journal of Hepatology, vol. 64, pp. 1247 - 1255, http://dx.doi.org/10.1016/j.jhep.2016.02.031
Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, vol. 16, http://dx.doi.org/10.1186/s12879-016-1567-2
Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0150655
Bourgeois S; Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Sulkowski M; Feld JJ; Carr V; Liu L; Ding X; McNally J; Osinusi A; Brainard DM; Subramanian M, 2016, 'SOF/VEL for 12 weeks is well tolerated and results in high SVR12 rates in people receiving opioid substitution therapy', HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, vol. 18, pp. 16 - 16, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000392945000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Leroy V; Angus P; Bronowicki JP; Dore GJ; Hezode C; Pianko S; Pol S; Stuart K; Tse E; Mcphee F; Bhore R; Jimenez-Exposito MJ; Thompson AJ, 2016, 'Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)', Hepatology, vol. 63, pp. 1430 - 1441, http://dx.doi.org/10.1002/hep.28473
Jacobson IM; Dore GJ; Foster GR, 2016, 'Erratum: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (Lancet (2014) 384 (403-13))', The Lancet, vol. 387, pp. 1816, http://dx.doi.org/10.1016/S0140-6736(16)30324-5
Jacobson IM; Dore GJ; Foster GR, 2016, 'Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (vol 384, pg 403, 2014)', LANCET, vol. 387, pp. 1816 - 1816, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000375056100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Dore GJ, 2016, 'Editorial commentary: Interferon-free Hepatitis C treatment efficacy from clinical trials will translate to "Real World" outcomes', Clinical Infectious Diseases, vol. 62, pp. 927 - 928, http://dx.doi.org/10.1093/cid/civ1227
MacParland SA; Fadel SM; Mihajlovic V; Fawaz A; Kim C; Nur-Ur Rahman AKM; Liu J; Kaul R; Kovacs C; Grebely J; Dore GJ; Wong DK; Ostrowski MA, 2016, 'HCV specific IL-21 producing T cells but not IL-17A producing T cells are associated with HCV viral control in HIV/HCV coinfection', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0154433
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, vol. 3, http://dx.doi.org/10.1093/ofid/ofw105
Hezode C; Dore GJ; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', GASTROENTEROLOGY, vol. 150, pp. S1096 - S1096, http://dx.doi.org/10.1016/S0016-5085(16)33701-5
Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, vol. 13, http://dx.doi.org/10.1186/s12985-016-0482-x
Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE, 2016, 'Hepatitis c virus treatment and persons who inject drugs', Annals of Internal Medicine, vol. 164, pp. 203, http://dx.doi.org/10.7326/L15-0485
Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2016, 'Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study', Addiction, vol. 111, pp. 311 - 319, http://dx.doi.org/10.1111/add.13197
Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J, 2016, 'FibroGENE: A gene-based model for staging liver fibrosis', Journal of Hepatology, vol. 64, pp. 390 - 398, http://dx.doi.org/10.1016/j.jhep.2015.11.008
Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, vol. 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028
Day CA; Shanahan M; Wand H; Topp L; Haber PS; Rodgers C; Deacon R; Walsh N; Kaldor J; van Beek I; Maher L; Lloyd A; Dore GJ; Walsh N, 2016, 'Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial', Journal of Clinical Virology, vol. 74, pp. 66 - 72, http://dx.doi.org/10.1016/j.jcv.2015.11.031
Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2016, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.11.009
Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T, 2016, 'Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials', Journal of Hepatology, vol. 64, pp. 19 - 28, http://dx.doi.org/10.1016/j.jhep.2015.08.015
Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, vol. 18, pp. 69 - 80
Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, vol. 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
Page K; Mirzazadeh A; Rice TM; Grebely J; Kim AY; Cox AL; Morris MD; Hellard M; Bruneau J; Shoukry NH; Dore GJ; Maher L; Lloyd AR; Lauer G; Prins M; McGovern BH, 2016, 'Interferon lambda 4 genotype is associated with jaundice and elevated aminotransferase levels during acute hepatitis C virus infection: Findings from the InC3 collaborative', Open Forum Infectious Diseases, vol. 3, http://dx.doi.org/10.1093/ofid/ofw024
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, vol. 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, vol. 21, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2016, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.11.011
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, vol. 21, pp. 465, http://dx.doi.org/10.3851/IMP3073
Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy', Journal of Hepatology, vol. 64, pp. S776 - S776, http://dx.doi.org/10.1016/s0168-8278(16)01513-0
Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study', Journal of Hepatology, vol. 64, pp. S776 - S777, http://dx.doi.org/10.1016/s0168-8278(16)01514-2
Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', Journal of Hepatology, vol. 64, pp. S753 - S754, http://dx.doi.org/10.1016/s0168-8278(16)01469-0
Moussalli J; Dore G; Platt H, 2016, 'COL 4-04 - C-EDGE CO-STAR : efficacité de l’elbasvir et du grazoprévir chez les utilisateurs de drogues injectables (UDI) recevant un traitement par agoniste des récepteurs opioïdes', Médecine et Maladies Infectieuses, vol. 46, pp. 9 - 9, http://dx.doi.org/10.1016/s0399-077x(16)30274-8
Gastroenterology CAO; For The Study Of The Liver CA, 2016, 'Program and Abstracts from the Canadian Digestive Diseases Week™ 2016.', Can J Gastroenterol Hepatol, vol. 2016, pp. 4792898, http://dx.doi.org/10.1155/2016/4792898
Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ, 2015, 'Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort', Journal of Viral Hepatitis, vol. 22, pp. 1020 - 1032, http://dx.doi.org/10.1111/jvh.12429
Aghemo A; Dore GJ; Hatzakis A; Wedemeyer H; Razavi H, 2015, 'Estimating HCV disease burden - Volume 3 (editorial)', Journal of Viral Hepatitis, vol. 22, pp. 1 - 3, http://dx.doi.org/10.1111/jvh.12473
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CAM; Rajender Reddy K; Roberts SK, 2015, 'Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection', Annals of Internal Medicine, vol. 163, pp. 809 - 817, http://dx.doi.org/10.7326/M15-1014
Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J, 2015, 'The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study', International Journal of Drug Policy, vol. 26, pp. 1094 - 1102, http://dx.doi.org/10.1016/j.drugpo.2015.06.001
Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs', International Journal of Drug Policy, vol. 26, pp. 1039 - 1040, http://dx.doi.org/10.1016/j.drugpo.2015.07.008
Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2015, 'Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study', Journal of Viral Hepatitis, vol. 22, pp. 914 - 925, http://dx.doi.org/10.1111/jvh.12415
Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study', Journal of Infectious Diseases, vol. 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, vol. 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003
Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J, 2015, 'Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study', International Journal of Drug Policy, vol. 26, pp. 984 - 991, http://dx.doi.org/10.1016/j.drugpo.2015.07.002
Larney S; Grebely J; Hickman M; De Angelis D; Dore GJ; Degenhardt L, 2015, 'Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs', International Journal of Drug Policy, vol. 26, pp. 950 - 957, http://dx.doi.org/10.1016/j.drugpo.2015.07.010
Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2015, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, vol. 26, pp. 1028 - 1038, http://dx.doi.org/10.1016/j.drugpo.2015.07.005
Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ, 2015, 'Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia', International Journal of Drug Policy, vol. 26, pp. 992 - 998, http://dx.doi.org/10.1016/j.drugpo.2015.01.005
Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, vol. 26, pp. 893 - 898, http://dx.doi.org/10.1016/j.drugpo.2015.07.007
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A; Haber P; Carolyn D; Gregory D; Tawil V; Krahn M; Loveday S; Thein HH, 2015, 'Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia', International Journal of Drug Policy, vol. 26, pp. 999 - 1006, http://dx.doi.org/10.1016/j.drugpo.2015.07.006
Grebely J; Haire B; Taylor LE; Macneill P; Litwin AH; Swan T; Byrne J; Levin J; Bruggmann P; Dore GJ, 2015, 'Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?', Journal of Hepatology, vol. 63, pp. 779 - 782, http://dx.doi.org/10.1016/j.jhep.2015.06.014
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; InC , 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, vol. 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384
Martin NK; Vickerman P; Dore GJ; Hickman M, 2015, 'The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): The use of direct-acting antivirals as treatment for prevention', Current Opinion in HIV and AIDS, vol. 10, pp. 374 - 380, http://dx.doi.org/10.1097/COH.0000000000000179
Barua S; Greenwald R; Grebely J; Dore GJ; Swan T; Taylor LE, 2015, 'Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States', Annals of Internal Medicine, vol. 163, pp. 215 - 223, http://dx.doi.org/10.7326/M15-0406
Lamoury FMJ; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J; Dore GJ; Applegate TL, 2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0131437
Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J, 2015, 'FibroGENE: A gene-based model for staging liver fibrosis', Journal of Hepatology, http://dx.doi.org/10.1016/j.jhep.2015.11.008
Dore GJ; Feld JJ, 2015, 'Hepatitis C virus therapeutic development: In pursuit of "perfectovir', Clinical Infectious Diseases, vol. 60, pp. 1829 - 1836, http://dx.doi.org/10.1093/cid/civ197
Sievert W, 2015, 'HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths', MEDICAL JOURNAL OF AUSTRALIA, vol. 202, pp. VI - VI, http://dx.doi.org/10.5694/mja15.00165
Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD, 2015, 'Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis', JAMA - Journal of the American Medical Association, vol. 313, pp. 1736 - 1744, http://dx.doi.org/10.1001/jama.2015.3868
Cunningham EB; Applegate TL; Lloyd AR; Dore GJ; Grebely J, 2015, 'Mixed HCV infection and reinfection in people who inject drugs-impact on therapy', Nature Reviews Gastroenterology and Hepatology, vol. 12, pp. 218 - 230, http://dx.doi.org/10.1038/nrgastro.2015.36
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0122232
Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, vol. 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227
Bradshaw D; Lamoury F; Catlett B; Applegate TL; McAllister J; Dore GJ; Matthews GV; Danta M, 2015, 'A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals', Journal of Infectious Diseases, vol. 211, pp. 736 - 743, http://dx.doi.org/10.1093/infdis/jiu550
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; De Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA, 2015, 'Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection', Gastroenterology, vol. 148, pp. 355 - 366.e1, http://dx.doi.org/10.1053/j.gastro.2014.10.007
Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ, 2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, vol. 62, pp. 269 - 277, http://dx.doi.org/10.1016/j.jhep.2014.09.001
Wedemeyer H; Dore GJ; Ward JW, 2015, 'Estimates on HCV disease burden worldwide - Filling the gaps', Journal of Viral Hepatitis, vol. 22, pp. 1 - 5, http://dx.doi.org/10.1111/jvh.12371
Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F; Dolan K; Haber P; Rawlinson W; Treloar C; Dore G; Maher L, 2015, 'Transmitted/founder viruses rapidly escape from CD8+ T cell responses in acute hepatitis C virus infection', Journal of Virology, vol. 89, pp. 5478 - 5490, http://dx.doi.org/10.1128/JVI.03717-14
Eslam M; Hashem AM; Leung R; Romero-Gomez M; Berg T; Dore GJ; Chan HLK; Irving WL; Sheridan D; Abate ML; Adams LA; Mangia A; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Powell E; Nattermann J; Riordan S; McLeod D; Armstrong NJ; Douglas MW; Liddle C; Booth DR; George J; Ahlenstiel G; Ampuero J; Bassendine M; Wong VWS; Rosso C; White R; Mezzabotta L; Suppiah V; Michalk M; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2015, 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease', Nature Communications, vol. 6, http://dx.doi.org/10.1038/ncomms7422
Spelman T; Morris MD; Zang G; Rice T; Page K; Maher L; Lloyd A; Grebely J; Dore GJ; Kim AY; Shoukry NH; Hellard M; Bruneau J; Cox AL; Lauer G; McGovern BH; Prins M; Hahn J; Shiboski S; Mirzazadeh A; Alavi M; Bouchard R; Evans J; Grady B; Aneja J; Sacks-Davis R; Teutsch S; White B; Wells B; Applegate T; Matthews G; Yeung B; Schinkel J; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J, 2015, 'A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs', Journal of Epidemiology and Community Health, vol. 69, pp. 745 - 752, http://dx.doi.org/10.1136/jech-2014-205224
Applegate TL; Gaudieri S; Plauzolles A; Chopra A; Grebely J; Lucas M; Hellard M; Luciani F; Dore GJ; Matthews GV, 2015, 'Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C', Antiviral Therapy, vol. 20, pp. 199 - 208, http://dx.doi.org/10.3851/IMP2821
Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, vol. 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003
Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2015, 'Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.11.010
Bretaña N; Boelen L; Bull R; Teutsch S; White P; Lloyd A; Luciani F, 2015, 'Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012.', Emerging Infectious Diseases, vol. 21, pp. 765 - 774, http://dx.doi.org/10.3201/eid2105.141832
Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.07.007
Maher L; White B; Dore G; Lloyd A; Rawlinson W, 2015, 'Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Drug and Alcohol Dependence, vol. 146, pp. e191 - e191, http://dx.doi.org/10.1016/j.drugalcdep.2014.09.435
Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Tu1024 Plasma Interferon-γ-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', Gastroenterology, vol. 148, http://dx.doi.org/10.1016/s0016-5085(15)33713-6
Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', Gastroenterology, vol. 148, http://dx.doi.org/10.1016/s0016-5085(15)33704-5
Grebely J; Dore GJ; Kim AY; Lloyd A; Shoukry NH; Prins M; Page K, 2014, 'Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn', Hepatology, vol. 60, pp. 2127 - 2128, http://dx.doi.org/10.1002/hep.27163
Muir A; Poordad F; Lalezari JP; Everson GT; Dore GJ; Kwo P; Hezode C; Pockros PJ; Tran A; Ramji A; Yang R; Hughes EA; Swenson ES; Yin PD, 2014, 'All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/BMS-791325, +/- ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 Phase 3 SVR12 results', HEPATOLOGY, vol. 60, pp. 1267A - 1268A, http://dx.doi.org/10.1002/hep.27589
Razavi H; Bruggmann P; Wedemeyer H; Dore G, 2014, 'Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: A comment on the results presented in JVH Special Issue', Journal of Viral Hepatitis, vol. 21, pp. e169 - e170, http://dx.doi.org/10.1111/jvh.12339
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
Jacka B; Applegate T; Krajden M; Olmstead A; Harrigan PR; Marshall BDL; Debeck K; Milloy MJ; Lamoury F; Pybus OG; Lima VD; Magiorkinis G; Montoya V; Montaner J; Joy J; Woods C; Dobrer S; Dore GJ; Poon AFY; Grebely J, 2014, 'Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada', Hepatology, vol. 60, pp. 1571 - 1580, http://dx.doi.org/10.1002/hep.27310
Shiffman ML; Cheinquer H; Berg CP; Berg T; de Figueiredo-Mendes C; Dore GJ; Ferraz ML; Mendes-Corrêa MC; Lima MP; Parise ER; Rios AMP; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F; Bakalos G; Zeuzem S, 2014, 'Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial', Hepatology International, vol. 8, pp. 517 - 526, http://dx.doi.org/10.1007/s12072-014-9555-3
Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, vol. 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010
Luciani F; Bretaña NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), vol. 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643
Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 29, pp. 85 - 85, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 29, pp. 85 - 86, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Luciani F; Bretaña NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), vol. 109, pp. 1695 - 1706, http://dx.doi.org/10.1111/add.12643
Harrod ME; Couzos S; Delaney-Thiele D; Dore GJ; Hammond B; Saunders M; Belfrage M; Williams S; Kaldor JM; Ward J, 2014, 'Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health services', Medical Journal of Australia, vol. 201, pp. 339 - 342, http://dx.doi.org/10.5694/mja14.00121
White B; Dore GJ; Lloyd AR; Rawlinson WD; Maher L, 2014, 'Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Medical Journal of Australia, vol. 201, pp. 326 - 329, http://dx.doi.org/10.5694/mja13.00153
Crane M; Avihingsanon A; Rajasuriar R; Velayudham P; Iser D; Solomon A; Sebolao B; Tran A; Spelman T; Matthews G; Cameron P; Tangkijvanich P; Dore GJ; Ruxrungtham K; Lewin SR, 2014, 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy', Journal of Infectious Diseases, vol. 210, pp. 745 - 751, http://dx.doi.org/10.1093/infdis/jiu119
Boelen L; Teutsch S; Wilson DP; Dolan K; Dore GJ; Lloyd AR; Luciani F, 2014, 'Per-event probability of hepatitis C infection during sharing of injecting equipment', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0100749
Grebely J; Lima VD; Marshall BDL; Milloy MJ; DeBeck K; Montaner J; Simo A; Krajden M; Dore GJ; Kerr T; Wood E, 2014, 'Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0097726
Dore GJ; Ward J; Thursz M, 2014, 'Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)', Journal of viral hepatitis, vol. 21, pp. 1 - 4, http://dx.doi.org/10.1111/jvh.12253
Bruggmann P; Berg T; Øvrehus ALH; Moreno C; Brandão Mello CE; Roudot-Thoraval F; Marinho RT; Sherman M; Ryder SD; Sperl J; Akarca U; Balık I; Bihl F; Bilodeau M; Blasco AJ; Buti M; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Ergör G; Esmat G; Estes C; Falconer K; Félix J; Ferraz MLG; Ferreira PR; Frankova S; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Gower E; Gschwantler M; Guimarães Pessôa M; Hézode C; Hofer H; Husa P; Idilman R; Kåberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lázaro P; Marotta P; Mauss S; Mendes Correa MC; Müllhaupt B; Myers RP; Negro F; Nemecek V; Örmeci N; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Rosenberg WM; Sarmento-Castro R; Sarrazin C; Semela D; Shiha GE; Sievert W; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; van Thiel I; Van Vlierberghe H; Vandijck D; Vogel W; Waked I; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Van Damme P; Aleman S; Hindman SJ, 2014, 'Historical epidemiology of hepatitis C virus (HCV) in selected countries', Journal of viral hepatitis, vol. 21, pp. 5 - 33, http://dx.doi.org/10.1111/jvh.12247
Razavi H; Waked I; Sarrazin C; Myers RP; Idilman R; Calinas F; Vogel W; Mendes Correa MC; Hézode C; Lázaro P; Akarca U; Aleman S; Balık I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandão Mello CE; Bruggmann P; Buti M; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Ergör G; Esmat G; Falconer K; Félix J; Ferraz MLG; Ferreira PR; Frankova S; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Gower E; Gschwantler M; Guimarães Pessôa M; Hindman SJ; Hofer H; Husa P; Kåberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Marinho RT; Marotta P; Mauss S; Moreno C; Murphy K; Negro F; Nemecek V; Örmeci N; Øvrehus ALH; Parkes J; Pasini K; Peltekian KM; Ramji A; Reis N; Roberts SK; Rosenberg WM; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Semela D; Sherman M; Shiha GE; Sievert W; Sperl J; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Van Vlierberghe H; Vandijck D; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Cornberg M; Müllhaupt B; Estes C, 2014, 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', Journal of viral hepatitis, vol. 21, pp. 34 - 59, http://dx.doi.org/10.1111/jvh.12248
Wedemeyer H; Duberg AS; Buti M; Rosenberg WM; Frankova S; Esmat G; Örmeci N; Van Vlierberghe H; Gschwantler M; Akarca U; Aleman S; Balık I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandão Mello CE; Bruggmann P; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; El-Sayed MH; Ergör G; Estes C; Falconer K; Félix J; Ferraz MLG; Ferreira PR; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Guimarães Pessôa M; Hézode C; Hindman SJ; Hofer H; Husa P; Idilman R; Kåberg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lázaro P; Marinho RT; Marotta P; Mauss S; Mendes Correa MC; Moreno C; Müllhaupt B; Myers RP; Nemecek V; Øvrehus ALH; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Sarrazin C; Semela D; Sherman M; Shiha GE; Sperl J; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Vandijck D; Vogel W; Waked I; Weis N; Wiegand J; Yosry A; Zekry A; Negro F; Sievert W; Gower E, 2014, 'Strategies to manage hepatitis C virus (HCV) disease burden', Journal of viral hepatitis, vol. 21, pp. 60 - 89, http://dx.doi.org/10.1111/jvh.12249
Bradshaw D; Lamoury F; Catlett B; Mcallister J; Applegate T; Dore G; Matthews G; Danta M, 2014, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-infected men with acute HCV', HIV MEDICINE, vol. 15, pp. 8 - 8, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000333652300024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Bradshaw D; Applegate T; Dore G; Hellard M; Sasadeusz J; Matthews G; Danta M, 2014, 'The majority of acute HCV infection in HIV-positive men who have sex with men (HIV plus MSM) is transmitted permucosally in the context of HIV serosorting in Australia', HIV MEDICINE, vol. 15, pp. 137 - 137, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000333652300421&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L, 2014, 'Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011', Journal of Viral Hepatitis, vol. 21, pp. 198 - 207, http://dx.doi.org/10.1111/jvh.12129
Martin NK; Devine A; Eaton JW; Miners A; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P, 2014, 'Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa', AIDS, vol. 28, http://dx.doi.org/10.1097/QAD.0000000000000084
Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2014, 'Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents', Liver International, vol. 34, pp. 1198 - 1206, http://dx.doi.org/10.1111/liv.12370
Treloar C; Rance J; Dore GJ; Grebely J, 2014, 'Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study', Journal of Viral Hepatitis, vol. 21, pp. 560 - 567, http://dx.doi.org/10.1111/jvh.12183
Roberts SK; Mitchell J; Leung R; Booth D; Bollipo S; Ostapowicz G; Sloss A; Mccaughan GW; Dore GJ; Thompson A; Crawford DH; Sievert W; Weltman M; Cheng W; George J; Angus P; Chu G; Cornwall M; Douglas M; Hallinan R; Haque M; Hawkin G; Jackson H; Johnson R; Kronborg I; Lee A; Leggett B; Mire ML; Levy M; Lubel J; MacQuillan G; Masson J; McDonald J; McGarity B; Mollison L; Nicoll A; Ombiga J; Riordan S; Roberts S; Strasser S; Thompson A; Watson J; Wenman J; Wigg A; Zekry A, 2014, 'Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies', Journal of Gastroenterology and Hepatology (Australia), vol. 29, pp. 179 - 184, http://dx.doi.org/10.1111/jgh.12424
Grebely J; Dore GJ, 2014, 'Can hepatitis C virus infection be eradicated in people who inject drugs?', Antiviral Research, vol. 104, pp. 62 - 72, http://dx.doi.org/10.1016/j.antiviral.2014.01.002
Grebely J; Grady B; Hajarizadeh B; Page K; Dore GJ, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, vol. 59, pp. 1650 - 1651, http://dx.doi.org/10.1002/hep.26675
Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; Mcgovern BH; Schinkel J; George J; Shoukry NH; Lauer GM; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, vol. 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639
Alavi M; Law MG; Grebely J; Thein HH; Walter S; Amin J; Dore GJ, 2014, 'Lower life expectancy among people with an HCV notification: A population-based linkage study', Journal of Viral Hepatitis, vol. 21, http://dx.doi.org/10.1111/jvh.12245
Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; Mccaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ, 2014, 'ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response', Hepatology, vol. 59, pp. 2152 - 2160, http://dx.doi.org/10.1002/hep.27022
Kitson MT; George J; Dore GJ; Leung R; Button P; Mccaughan GW; Crawford DHG; Sievert W; Weltman MD; Cheng WSC; Roberts SK, 2014, 'Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection', Journal of Gastroenterology and Hepatology (Australia), vol. 29, pp. 1458 - 1462, http://dx.doi.org/10.1111/jgh.12544
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ, 2014, 'Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia', Journal of Gastroenterology and Hepatology (Australia), vol. 29, pp. 1 - 9, http://dx.doi.org/10.1111/jgh.12677
Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, vol. 26, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150
Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, vol. 44, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M, 2014, 'Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial', The Lancet, vol. 384, pp. 403 - 413, http://dx.doi.org/10.1016/S0140-6736(14)60494-3
White B; Madden A; Prins M; Hellard M; Wand H; Dore GJ; Page K; Maher L, 2014, 'Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study', Vaccine, vol. 32, pp. 5460 - 5467, http://dx.doi.org/10.1016/j.vaccine.2014.07.091
Peters L; Neuhaus J; Duprez D; Neaton JD; Tracy R; Klein MB; Mocroft A; Rockstroh J; Dore G; Lundgren JD, 2014, 'Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study', Journal of Clinical Virology, vol. 60, pp. 295 - 300, http://dx.doi.org/10.1016/j.jcv.2014.03.017
Treloar C; Rance J, 2014, 'How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting', International Journal of Drug Policy, vol. 25, pp. 865 - 870, http://dx.doi.org/10.1016/j.drugpo.2014.01.011
Treloar C; Rance J; Grebely J; Dore GJ, 2013, 'Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia', Drug and Alcohol Dependence, vol. 133, pp. 529 - 534, http://dx.doi.org/10.1016/j.drugalcdep.2013.07.023
Fried MW; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson I; Marcellin P; Manns M; Nikitin I; Poordad F; Sherman M; Zeuzem S; Scott J; Gilles L; Lenz O; Peeters M; Sekar V; De Smedt G; Beumont-Mauviel M, 2013, 'Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study', Hepatology, vol. 58, pp. 1918 - 1929, http://dx.doi.org/10.1002/hep.26641
Feld JJ; Grebely J; Matthews GV; Applegate T; Hellard M; Sherker A; Cherepanov V; Petoumenos K; Yeung B; Kaldor JM; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0080003
Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M, 2013, 'Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals', Hepatology, vol. 58, pp. 1598 - 1609, http://dx.doi.org/10.1002/hep.26431
Grebely J; Matthews GV; Lloyd AR; Dore GJ, 2013, 'Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements', Clinical Infectious Diseases, vol. 57, pp. 1014 - 1020, http://dx.doi.org/10.1093/cid/cit377
Holmes JA; Roberts SK; Sievert W; Dore GJ; Mccaughan M; Crawford DJ; Cheng W; Weltman M; Bonanzinga S; Visvanathan K; Desmond PV; Bowden DS; Matthews G; Thompson AJ, 2013, 'RBV pharmacokinetics explain the relationship between on-treatment anaemia and SVR, which is independent of ITPA genotype: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 28, pp. 171 - 172, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Eslam M; Leung R; Berg T; Irving WL; Mangia A; Sheridan D; Abate ML; Weltman M; Spengler U; Mollison L; Cheng W; Dore GJ; Powell E; Riordan S; Douglas M; Suppiah V; Stewart GJ; Booth DR; George J; Ahlenstiel G, 2013, 'Association of IFNL3 polymorphisms with fibrosis progression in viral and non-viral chronic liver disease', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 28, pp. 67 - 67, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Strasser SI; Roberts SK; Gane EJ; Macdonald GA; Thompson AJ; Weltman MD; Weilert F; Hill A; Laeuffer J; Dore GJ, 2013, 'Management and outcomes of side effects with focus on anaemia in patients with hepatitis c genotype 1 infection: The telaprevir early access program in patients from Australia and New Zealand', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 28, pp. 168 - 169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900348&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ; Lawitz E; Hezode C; Shafran S; Ramji A; Tatum H; Taliani G; Tran A; Brunetto M; Zaltron S; Strasser S; Weis N; Ghesquiere W; Lee S; Larrey D; Pol S; Harley H; George J; Fung S; De Ledinghen V; Hagens P; Cohen D; Cooney E; Noviello S; Hughes E, 2013, 'Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 28, pp. 155 - 156, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900327&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Macdonald GA; Roberts SK; Dore GJ; Gane EJ; Thompson AJ; Weltman MD; Weilert F; Hill A; Laeuffer J; Strasser SI, 2013, 'Treatment of hepatitis c genotype 1 patients with severe fibrosis or compensated cirrhosis: The telaprevir early access program in patients from Australia and New Zealand', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 28, pp. 169 - 169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900350&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, vol. 10, pp. 553 - 562, http://dx.doi.org/10.1038/nrgastro.2013.107
Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2013, 'Assessment and treatment of hepatitis c virus infection among people who inject drugs in the opioid substitution setting: ETHOS study', Clinical Infectious Diseases, vol. 57, http://dx.doi.org/10.1093/cid/cit305
Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ, 2013, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', Clinical Infectious Diseases, vol. 57, http://dx.doi.org/10.1093/cid/cit302
Aspinall EJ; Corson S; Doyle JS; Grebely J; Hutchinson SJ; Dore GJ; Goldberg DJ; Hellard ME, 2013, 'Treatment of hepatitis c virus infection among people who are actively injecting drugs: A systematic review and meta-analysis', Clinical Infectious Diseases, vol. 57, http://dx.doi.org/10.1093/cid/cit306
White B; Madden A; Hellard M; Kerr T; Prins M; Page K; Dore GJ; Maher L, 2013, 'Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs', Drug and Alcohol Review, vol. 32, pp. 419 - 425, http://dx.doi.org/10.1111/dar.12000
Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'Sequencing of the Hepatitis C Virus: A Systematic Review', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0067073
Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, vol. 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263
Hegerle N; Rayat L; Dore G; Zidane N; Bedouelle H; Guiso N, 2013, 'In-vitro and in-vivo analysis of the production of the Bordetella type three secretion system effector A in Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica', Microbes and Infection, vol. 15, pp. 399 - 408, http://dx.doi.org/10.1016/j.micinf.2013.02.006
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA, 2013, 'Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 28, pp. 1770 - 1781, http://dx.doi.org/10.1111/jgh.12265
Kitson MT; Dore GJ; George J; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Robertson S, 2013, 'Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection', Journal of Hepatology, vol. 58, pp. 467 - 472, http://dx.doi.org/10.1016/j.jhep.2012.11.017
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond RA; Bowden S; Lewin SR; Sasadeusz JJ; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ, 2013, 'Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals', PLoS One, vol. 8, pp. e61297, http://dx.doi.org/10.1371/journal.pone.0061297
Matthews G; Seaberg E; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz JJ; Revill PA; Littlejohn M; Hoy J; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio C, 2013, 'Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus', Clinical Infectious Diseases, vol. 56, pp. e87 - e94, http://dx.doi.org/10.1093/cid/cit002
Post J; Arain A; Lloyd AR, 2013, 'Enhancing Assessment and Treatment Hepatitis C in the Custodial Setting', Clinical Infectious Diseases, vol. 57, pp. S70 - S74, http://dx.doi.org/10.1093/cid/cit264
Grebely J; Oser ML; Taylor L; Dore GJ, 2013, 'Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels', Journal of Infectious Diseases, vol. 207, pp. S19 - S25, http://dx.doi.org/10.1093/infdis/jis928
Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, vol. 14, pp. 286 - 290, http://dx.doi.org/10.1038/gene.2013.15
Deans GD; Raffa JD; Lai C; Fischer B; Krajden M; Amin J; Walter SR; Dore GJ; Grebely J; Tyndall MW, 2013, 'Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada.', CMAJ Open, vol. 1, pp. E68 - E76, http://dx.doi.org/10.9778/cmajo.20130002
Jacobson IM; Dore GJ; Foster G; Fried MW; Radu MN; Rafalskiy VV; Moroz L; Craxi;ag A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial', Gastroenterology, vol. 144, pp. S - 374, http://dx.doi.org/10.1016/s0016-5085(13)61381-5
Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, vol. 31, pp. 34 - 34, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, vol. 31, pp. 33 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Holmes JA; Bonanzinga S; Roberts S; Sievert W; Dore G; Mccaughan G; Crawford DH; Cheng W; Weltman MD; Matthews G; Visvanathan K; Desmond P; Bowden DS; Thompson A, 2012, 'ITPA genotype strongly protects from ribavirin-induced haemolytic anaemia: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 27, pp. 168 - 168, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N, 2012, 'Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: Increase of Bordetellae not expressing pertactin', Clinical Microbiology and Infection, vol. 18, http://dx.doi.org/10.1111/j.1469-0691.2012.03925.x
Crawford DHG; Dore GJ; Sievert W; Cheng WSC; Weltman M; McCaughan G; Rawlinson WD; Marks P; Yoshihara M; Rizkalla B; Roberts SK, 2012, 'Early on-treatment viral load and baseline METAVIR score: Improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, vol. 17, pp. 849 - 854, http://dx.doi.org/10.3851/IMP2104
Treloar C; Hull PB; Dore GJ; Grebely J, 2012, 'Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs', Drug and Alcohol Review, vol. 31, pp. 918 - 924, http://dx.doi.org/10.1111/j.1465-3362.2012.00468.x
Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x
Kwon J; Anderson JS; Kerr CC; Thein H; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP, 2012, 'Estimating the cost-effectiveness of needle-syringe programs in Australia.', AIDS, vol. 26, pp. 2201 - 2210, http://dx.doi.org/10.1097/QAD.0b013e3283578b5d
Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz JJ; Cooper DA; Bowden S; Locarnini SA; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, vol. 9, pp. Article number 6, http://dx.doi.org/10.1186/1742-6405-9-6
Grebely J; Pham ST; Matthews G; Petoumenos K; Bull RA; Yeung B; Rawlinson WD; Kaldor JM; Lloyd AR; Hellard M; Dore GJ; White PA; Bull , 2012, 'Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection', Hepatology, vol. 55, pp. 1058 - 1069, http://dx.doi.org/10.1002/hep.24754
Flynn J; Dore GJ; Matthews G; Hellard M; Yeung B; Rawlinson W; White PA; Kaldor JM; Lloyd AR; Ffrench RA, 2012, 'Impaired hepatitis C virus (HCV)-specific interferon-responses in individuals with HIV who acquire HCV infection: Correlation with CD4 + T-cell counts', Journal of Infectious Diseases, vol. 206, pp. 1568 - 1576, http://dx.doi.org/10.1093/infdis/jis544
Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, vol. 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719
Thein H; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2012, 'Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort', Hepatology Research, vol. 42, pp. 1175 - 1186, http://dx.doi.org/10.1111/j.1872-034X.2012.01037.x
Gidding HF; Law MG; Amin J; Ostapowicz G; Weltman MD; Macdonald GAM; Sasadeusz JJ; Haber PS; George J; Dore GJ, 2012, 'Hepatitis C treatment outcomes in Australian clinics', Medical Journal of Australia, vol. 196, pp. 633 - 637, http://dx.doi.org/10.5694/mja12.10014
Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, vol. 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007
Grebely J; Dore GJ, 2012, 'What is killing people with hepatitis C virus infection?', Seminars in Liver Disease, vol. 31, pp. 331 - 339, http://dx.doi.org/10.1055/s-0031-1297922
Vickerman P; Grebely J; Dore GJ; Sacks-davis R; Page K; Thomas DL; Osburn WO; Cox AL; Aitken CL; Hickman M; Hellard M, 2012, 'The more you look, the more you find: Effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design', Journal of Infectious Diseases, vol. 205, pp. 1342 - 1350, http://dx.doi.org/10.1093/infdis/jis213
Grebely J; Prins M; Hellard M; Cox AL; Osburn WO; Lauer G; Page K; Lloyd AR; Dore GJ, 2012, 'Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine', Lancet Infectious Diseases, vol. 12, pp. 408 - 414, http://dx.doi.org/10.1016/S1473-3099(12)70010-5
White BA; Dore GJ; Lloyd AR; Rawlinson WD; Maher L, 2012, 'Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney', Australian and New Zealand Journal of Public Health, vol. 36, pp. 351 - 356, http://dx.doi.org/10.1111/j.1753-6405.2012.00881.x
Cowie BC; Dore GJ, 2012, 'The Perpetual Challenge of Infectious Diseases', New England Journal of Medicine, vol. 367, pp. 89 - 89, http://dx.doi.org/10.1056/NEJMc1201391
Dore GJ, 2012, 'The changing therapeutic landscape for hepatitis C.', Medical Journal of Australia, vol. 196, pp. 629 - 632, http://dx.doi.org/10.5694/mja11.11531
Grebely J; Morris M; Rice T; Bruneau J; Cox AL; Kim A; McGovern B; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Prins M; Dore GJ; Page K, 2012, 'Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.', International Journal of Epidemiology, vol. in press, pp. 1-11, http://dx.doi.org/10.1093/ije/dys167
Matthews GV; Dore GJ, 2011, 'HIV and Hepatitis C Co-Infection', Advanced Therapy for Hepatitis C, pp. 177 - 184, http://dx.doi.org/10.1002/9781444346343.ch22
Ewer P; Mills K; Teesson M; Sannibale C; Baker A; Kay-Lambkin F; Dore G, 2011, 'A BRIEF INTERVENTION FOR ALCOHOL AND OTHER DRUG USERS WHO HAVE EXPERIENCED TRAUMA', DRUG AND ALCOHOL REVIEW, vol. 30, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297019700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Peters L; Neuhaus J; Mocroft A; Soriano V; Rockstroh J; Dore G; Puoti M; Tedaldi E; Clotet B; Kupfer B; Lundgren JD; Klein MB, 2011, 'Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART study', Antiviral Therapy, vol. 16, pp. 667 - 675, http://dx.doi.org/10.3851/IMP1815
Sievert W; Dore GJ; Roberts SK, 2011, 'Reply', Hepatology, vol. 53, pp. 1775 - 1776, http://dx.doi.org/10.1002/hep.24250
Matthews GV; Dore GJ, 2011, 'Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?', Hepatology, vol. 53, pp. 1055 - 1056, http://dx.doi.org/10.1002/hep.24152
Bouchez V; Brun D; Dore G; Njamkepo E; Guiso N, 2011, 'Bordetella parapertussis isolates not expressing pertactin circulating in France', Clinical Microbiology and Infection, vol. 17, pp. 675 - 682, http://dx.doi.org/10.1111/j.1469-0691.2010.03303.x
Grebely J; Bryant J; Hull PB; Hopwood MN; Lavis YM; Dore GJ; Treloar C, 2011, 'Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.', Journal of Viral Hepatitis, vol. 18, pp. 104 - 116, http://dx.doi.org/10.1111/j.1365
Grebely J; Dore GJ, 2011, 'What is killing people with HCV infection?', Seminars in Liver Disease, vol. 31, pp. 331 - 339
Suppiah V; Gaudieri S; Armstrong NJ; O''Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Muller T; Hammond E; Dunn ; Negro F; Bochud PY; Mallal SA; Ahlenstiel G; Stewart GJ; George J; Booth DR, 2011, 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: A cross-sectional study.', PLOS Medicine, vol. 8, pp. e1001092
Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford D; Cheng W; Weltman M; Rawlinson W; Rizkalla B; DePamphilis JK; Roberts SK, 2011, 'Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1', Hepatology, vol. 53, pp. 1109 - 1117, http://dx.doi.org/10.1002/hep.24180
Audsley J; Seaberg E; Sasadcusz J; Matthews G; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson RJ; Hwang H; Littlejohn M; Locarnini S; Dore GJ; Thio C; Lewin S, 2011, 'Factors associated with elevated ALT in an international HIV/HBV Co-Infected cohort on long-term HAART', PLoS One, vol. 6, pp. e26482, http://dx.doi.org/10.1371/journal.pone.0026482
Matthews G; Pham STP; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek IA; Rawlinson WD; Kaldor JM; Lloyd AR; Dore GJ; White PA, 2011, 'Patterns and characteristics of Hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C', Clinical Infectious Diseases, vol. 52, pp. 803 - 811, http://dx.doi.org/10.1093/cid/ciq200
Suppiah V; Gaudieri S; Armstrong N; O''connor K; Berg T; Weltman M; Abate M; Spengler U; Bassendine M; Dore G; Irving W; Powell E; Hellard M; Riordan S; Mathews G; Sheridan D; Natterman J; Smedile A; Muller T; Hammond E; Dunn D; Negro F; Bochud Y; Mallal S; Ahlenstiel G; Stewart G; George J; Booth D, 2011, 'IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection', PLOS Medicine, vol. 8, pp. e1001092, http://dx.doi.org/10.1371/journal.pmed.1001092
Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW, 2011, 'Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents', Journal of Viral Hepatitis, vol. 18, pp. 32 - 41, http://dx.doi.org/10.1111/j.1365-2893.2010.01279.x
Bull RA; Luciani F; McElroy K; Gaudieri S; Pham ST; Chopra A; Cameron B; Maher L; Dore GJ; White PA; Lloyd AR, 2011, 'Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection', PLoS Pathog, vol. 7, pp. e1002243, http://dx.doi.org/10.1371/journal.ppat.1002243
Dore GJ; Matthews GV; Rockstroh J, 2011, 'Future of hepatitis C therapy: Development of direct-acting antivirals', Current opinion in HIV & AIDS, vol. 6, pp. 508 - 513, http://dx.doi.org/10.1097/COH.0b013e32834b87f8
Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, vol. 55, pp. 76 - 85, http://dx.doi.org/10.1016/j.jhep.2010.10.033
Grebely J; Matthews G; Dore GJ, 2011, 'Treatment of acute HCV infection', Nature Reviews Gastroenterology and Hepatology, vol. 8, pp. 265 - 274, http://dx.doi.org/10.1038/nrgastro.2011.32
Walter SR; Thein H; Gidding HF; Amin J; George J; Dore GJ, 2011, 'Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C', Journal of Gastroenterology and Hepatology (JGH), vol. 26, pp. 1757 - 1764, http://dx.doi.org/10.1111/j.1440-1746.2011.06785.x
Gidding HF; Amin J; Dore GJ; Law MG, 2011, 'Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C', Epidemiology and Infection, vol. 139, pp. 1151 - 1158, http://dx.doi.org/10.1017/S095026881000258X
Thein HH; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2011, 'Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: A population-based cohort study, 1992-2007', Journal of Viral Hepatitis, vol. 18, pp. e232 - e241, http://dx.doi.org/10.1111/j.1365-2893.2011.01440.x
Walter SR; Thein HH; Amin J; Gidding HF; Ward K; Law MG; George J; Dore GJ, 2011, 'Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006', Journal of Hepatology, vol. 54, pp. 879 - 886, http://dx.doi.org/10.1016/j.jhep.2010.08.035
Gidding HF; Law MG; Amin J; MacDonald GJ; Sasadeusz JJ; Jones TL; Strasser SI; George J; Dore GJ, 2011, 'Predictors of deferral of treatment for hepatitis C infection in Australian clinics', The Medical Journal of Australia, vol. 194, pp. 398 - 402
Gidding HF; Dore GJ; Amin J; Law MG, 2011, 'Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study', BMC Public Health, vol. 11, pp. 52, http://dx.doi.org/10.1186/1471-2458-11-52
Grebely J; Dore GJ, 2011, 'Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity', Journal of Infectious Diseases, vol. 203, pp. 571 - 574, http://dx.doi.org/10.1093/infdis/jiq111
Grebely J; Dore GJ, 2011, 'Hepatitis C: Enhancing treatment for hepatitis C among drug users', Nature Reviews Gastroenterology and Hepatology, vol. 8, pp. 11 - 13, http://dx.doi.org/10.1038/nrgastro.2010.186
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA, 2011, 'Early IL-10 predominant responses are associated with progression from acute to chronic hepatitis C virus infection in injecting drug users', Journal of Viral Hepatitis, vol. 18, pp. 549 - 561, http://dx.doi.org/10.1111/j.1365-2893.2010.01335.x
Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S, 2011, 'Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients', Antiviral Therapy, vol. 16, pp. 173 - 180, http://dx.doi.org/10.3851/IMP1731
Grebely J; Dore GJ, 2011, 'An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community', Hepatology, vol. 54, pp. 2259 - 2261, http://dx.doi.org/10.1002/hep.24714
Smith KR; Suppiah V; O''Connor K; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Matthews G; Irving W; Powell E; Riordan S; Ahlensteil G; Stewart GJ; Bahlo M; Booth DR; George J, 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine, vol. 3, pp. 57, http://dx.doi.org/10.1186/gm273
Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2011, 'Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy', Addiction, vol. 106, pp. 977 - 984, http://dx.doi.org/10.1111/j.1360-0443.2010.03347.x
Grebely J; Matthews GV; Petoumenos K; Dore GJ, 2010, 'Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection', Journal of Viral Hepatitis, vol. 17, pp. 896, http://dx.doi.org/10.1111/j.1365-2893.2009.01256.x
Grebely J; Bryant J; Hull P; Hopwood M; Dore G; Treloar C, 2010, 'PRESENTER 2: SPECIALIST ASSESSMENT AND TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS IN NEW SOUTH WALES, AUSTRALIA', DRUG AND ALCOHOL REVIEW, vol. 29, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284895600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore G; Grebely J; Gillman A; Thein R; Day C; Ryan L; Treloar C; Haber P, 2010, 'PRESENTER 1: OVERVIEW OF TREATMENT OF HEPATITIS C (HCV) IN THE OPIATE PHARMACOTHERAPY SETTING AND THE ENHANCING TREATMENT OF HEPATITIS C IN THE OPIATE SUBSTITUTION SETTING (ETHOS) PARTNERSHIP INITIATIVE', DRUG AND ALCOHOL REVIEW, vol. 29, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284895600048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cheng W; Roberts S; McCaughan G; Sievert W; Weltman MD; Crawford D; Rawlinson WD; Marks P; Thommes J; Rizkalla B; Yoshihara M; Dore GJ, 2010, 'Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing', Journal of Hepatology, vol. 53, pp. 616 - 623, http://dx.doi.org/10.1016/j.jhep.2010.04.024
Dore GJ; Soriano V; Rockstroh J; Kupfer B; Tedaldi E; Peters L; Neuhaus J; Puoti M; Klein M; Mocroft A; Clotet B; Lundgren JD, 2010, 'Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption', AIDS, vol. 24, pp. 857 - 865, http://dx.doi.org/10.1097/QAD.0b013e328334bddb
Pham STP; Bull RA; Bennett JM; Rawlinson WD; Lloyd AR; Dore GJD; White PA; Bull , 2010, 'Frequent multiple hepatitis C virus infections among injection drug users in a prison setting', Hepatology, vol. 52, pp. 1564 - 1572, http://dx.doi.org/10.1002/hep.23885
Milner K; van der Poorten D; Trenell M; Jenkins AB; Xu A; Smythe GA; Dore GJ; Zekry A; Weltman MD; Fragomeli V; George J; Chisholm DJ, 2010, 'Chronic Hepatitis C is associated with peripheral rather than hepatic insulin resistance', Gastroenterology, vol. 138, pp. 932 - 941, http://dx.doi.org/10.1053/j.gastro.2009.11.050
Avihingsanon A; Lewin S; Kerr SJ; Chang JJ; Piyawat K; Napissanant N; Matthews G; Dore GJ; Bowden S; Lange J; Ruxrungtham K, 2010, 'Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-HBV coninfection in Thailand', Antiviral Therapy, vol. 15, pp. 917 - 922, http://dx.doi.org/10.3851/IMP1645
Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850
Audsley J; Yuen L; Littlejohn M; Sasadcusz J; Ayres A; Desmond C; Spelman T; Lau GT; Matthews G; Avihingsanon A; Seaberg E; Philp F; Saulynas M; Ruxrungtham K; Dore GJ; Locarnini S; Thio C; Lewin S; Revill P, 2010, 'HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing', Virology, vol. 405, pp. 539 - 547, http://dx.doi.org/10.1016/j.virol.2010.06.038
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, vol. 138, pp. 123 - 135, http://dx.doi.org/10.1053/j.gastro.2009.09.019
Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, vol. 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015
Crane M; Sirivichayakul S; Chang JJ; Avihingsanon A; Ubolyam S; Buranapraditkun S; Thantiworasit P; Wightman F; Locarnini S; Matthews G; Dore GJ; Ruxrungtham K; Lewin SR, 2010, 'No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy', Journal of Virology, vol. 84, pp. 2657 - 2665, http://dx.doi.org/10.1128/JVI.02124-09
Teutsch S; Luciani F; Scheuer N; McCredie L; Hosseiny P; Rawlinson WD; Kaldor JM; Dore GJ; Dolan K; Ffrench R; Lloyd AROLA; Haber P; Levy MH, 2010, 'Incidence of primary Hepatitis C infection and risk factors for transmission in an Australian prisoner cohort', BMC Public Health, vol. 10, pp. 1 - 9, http://dx.doi.org/10.1186/1471-2458-10-633
Gidding HF; Amin J; Dore GJ; Ward K; Law MG, 2010, 'Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia', Journal of Hepatology, vol. 53, pp. 43 - 49, http://dx.doi.org/10.1016/j.jhep.2010.01.036
Grebely J; Knight E; Ngai T; Genoway K; Raffa J; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2010, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, vol. 25, pp. 1281 - 1284, http://dx.doi.org/10.1111/j.1440-1746.2010.06238.x
Day C; White B; Dore G; Van Beek I; Rodgers C; Cunningham P; Wodak A; Maher L, 2010, 'Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status', Drug and Alcohol Dependence, vol. 108, pp. 134 - 137, http://dx.doi.org/10.1016/j.drugalcdep.2009.11.013
Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', Gastroenterology, vol. 138, pp. S - 844, http://dx.doi.org/10.1016/s0016-5085(10)63886-3
Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2009, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, http://dx.doi.org/10.1111/j.1440-1746.2009.06238.x
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, vol. 28, pp. A27 - A27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Bouchez V; Brun D; Cantinelli T; Dore G; Njamkepo E; Guiso N, 2009, 'First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin', Vaccine, vol. 27, pp. 6034 - 6041, http://dx.doi.org/10.1016/j.vaccine.2009.07.074
Matthews GV; Hellard M; Dore GJ, 2009, 'Reply', Clinical Infectious Diseases, vol. 49, pp. 319, http://dx.doi.org/10.1086/600059
Roberts S; Weltman M; Crawford D; Mccaughan GW; Sievert W; Cheng W; Rawlinson WD; Desmond PV; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patients with Hepatitis C Genotype 1: a Randomized Controlled Trial', Hepatology, vol. 50, pp. 1045 - 1055, http://dx.doi.org/10.1002/hep.23130
Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French MA; Ruxrungtham K; Lewin S, 2009, 'Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy', Journal of Infectious Diseases, vol. 199, pp. 974 - 981, http://dx.doi.org/10.1086/597276
Razali K; Amin J; Dore GJ; Law MG, 2009, 'Modelling and calibration of the hepatitis C epidemic in Australia', Statistical Methods in Medical Research, vol. 18, pp. 253 - 270, http://dx.doi.org/10.1177/0962280208094689
Chang JH; Sirivichayakul S; Avihingsanon A; Thompson A; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G; Cooper DA; Kent SJ; Cameron P; Sasadeusz J; Desmond PV; Locarnini S; Dore GJ; Ruxrungtham K; Lewin S, 2009, 'Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection', Journal of Virology, vol. 83, pp. 7649 - 7658, http://dx.doi.org/10.1128/JVI.00183-09
van de Laar T; Pybus O; Bruisten S; Brown D; Nelson M; Bhagani S; Vogel M; Baumgarten A; Chaix M; Fisher M; Gotz H; Matthews G; Neifer S; White PA; Rawlinson W; Pol S; Rockstroh J; Coutinho RA; Dore GJ; Dusheiko GM; Danta M, 2009, 'Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men', Gastroenterology, vol. 136, pp. 1609 - 1617, http://dx.doi.org/10.1053/j.gastro.2009.02.006
Matthews G; Hellard M; Haber P; Yeung B; Marks PB; Baker D; McCaughan G; Sasadeusz J; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in acute hepatitis C', Clinical Infectious Diseases, vol. 48, pp. 650 - 658, http://dx.doi.org/10.1086/596770
Lewin S; Ribiero R; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini S; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, vol. 49, pp. 1113 - 1121, http://dx.doi.org/10.1002/hep.22754
Suppiah V; Moldovan M; Ahlenstiel G; Berg T; Weltman M; Abate M; Bassendine M; Spengler U; Dore GJ; Powell E; Riordan SM; Sheridan D; Smedile A; Fragomeli V; Muller T; Bahlo M; Stewart GJ; Booth D; George J, 2009, 'IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy', Nature Genetics, vol. 41, pp. 1100 - 1104, http://dx.doi.org/10.1038/ng.447
Gidding H; Topp L; Middleton M; Robinson K; Hellard M; McCaughan G; Maher L; Kaldor J; Dore G; Law M, 2009, 'The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006', Journal of Gastroenterology and Hepatology, vol. 24, pp. 1648 - 1654, http://dx.doi.org/10.1111/j.1440-1746.2009.05910.x
Grebely J; Thomas D; Dore GJ, 2009, 'HCV reinfection studies and the door to vaccine development', Journal of Hepatology, vol. 51, pp. 628 - 631, http://dx.doi.org/10.1016/j.jhep.2009.07.002
Topp L; Day C; Dore G; Maher L, 2009, 'Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review', Drug and Alcohol Review, vol. 28, pp. 669 - 675, http://dx.doi.org/10.1111/j.1465-3362.2009.00060.x
Doab A; Topp L; Day C; Dore G; Maher L, 2009, 'Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study', Contemporary Clinical Trials, vol. 30, pp. 431 - 435, http://dx.doi.org/10.1016/j.cct.2009.04.002
Nguyen VT; Amin J; Law MG; Dore GJ, 2009, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia', Journal of Gastroenterology and Hepatology, vol. 24, pp. 436 - 442, http://dx.doi.org/10.1111/j.1440-1746.2008.05577.x
Nguyen VT; Law MG; Dore GJ, 2009, 'Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden', Journal of Viral Hepatitis, vol. 16, pp. 453 - 463, http://dx.doi.org/10.1111/j.1365-2893.2009.01117.x
Thein H; Dore GJ, 2009, 'Trends in chronic viral hepatitis: Notifications, treatment uptake and advanced disease burden', Cancer Forum, vol. 33, pp. 97 - 105
Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT; Penman A, 2009, 'Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer', Journal of Hepatology, vol. 50, pp. 990 - 998, http://dx.doi.org/10.1016/j.jhep.2008.12.022
Matthews G; Seaberg E; Dore GJ; Bowden S; Lewin S; Sasadeusz J; Marks P; Goodman Z; Philp F; Tang Y; Locarnini S; Thio C, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, vol. 23, pp. 1707 - 1715, http://dx.doi.org/10.1097/QAD.0b013e32832b43f2
Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', Asian Biomedicine, vol. 3, pp. 29 - 37
Matthews G; Hellard M; Dore GJ, 2009, 'Initial Presentation of Acute Hepatitis C Virus (HCV) Infection among HIV-Negative and HIV-Positive Individuals-Experience from 2 Large German Networks on the Study of Acute HCV Infection Reply', Clinical Infectious Diseases, vol. 49, pp. 319 - 319, http://dx.doi.org/10.1086/600059
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White PA; Ffrench R; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2009, 'Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study', The Canadian Journal of Addiction, vol. 1, pp. 33 - 33, http://dx.doi.org/10.1097/02024458-200912000-00072
Grebely J; Raffa JD; Lai C; Kerr T; Krajden M; Kerr T; Dore GJ; Tyndall MW, 2008, 'Impact of HCV and HIV infections on mortality in a large community-based cohort of inner city residents', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 23, pp. A379 - A380, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Doré G; Leclerc C; Lazarini F, 2008, 'Treatment by CpG or Flt3-ligand does not affect mouse susceptibility to BSE prions', Journal of Neuroimmunology, vol. 197, pp. 74 - 80, http://dx.doi.org/10.1016/j.jneuroim.2008.03.016
Jin F; Prestage GP; Dore GJ; Zablotska I; Rawstorne P; Kippax SC; Kaldor JM; Grulich AE, 2008, 'PREVALENCE, INCIDENCE AND RISK FACTORS FOR HEPATITIS C IN HIV NEGATIVE AND HIV POSITIVE HOMOSEXUAL MEN', SEXUAL HEALTH, vol. 5, pp. 389 - 389, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000260999000039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Tedaldi E; Peters L; Neuhaus J; Puoti M; Rockstroh J; Klein M; Dore GJ; Mocroft A; Soriano V; Clotet B; Lundgren JD, 2008, 'Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study', Clinical Infectious Diseases, vol. 47, pp. 1468 - 1475, http://dx.doi.org/10.1086/593102
Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2008, 'Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries', Journal of Gastroenterology and Hepatology, vol. 23, pp. 922 - 929, http://dx.doi.org/10.1111/j.1440-1746.2007.05065.x
Matthews G; Avihingsanon A; Lewin S; Amin J; Rerknimitr R; Petcharapirat P; Marks PB; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, vol. 48, pp. 1062 - 1069, http://dx.doi.org/10.1002/hep.22462
Preiss S; Littlejohn M; Angus PA; Thompson A; Desmond PV; Lewin S; Sasadeusz J; Matthews G; Dore GJ; Shaw T; Sozzi V; Yuen L; Lau GT; Ayres A; Thio C; Avihingsanon A; Ruxrungtham K; Locarnini S; Revill P, 2008, 'Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance', Hepatology, vol. 48, pp. 741 - 749, http://dx.doi.org/10.1002/hep.22386
Matthews G; Grebely J; Dore GJ, 2008, 'The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure', Journal of Hepatology, vol. 49, pp. 305 - 307, http://dx.doi.org/10.1016/j.jhep.2008.06.005
Matthews G; Dore GJ, 2008, 'HIV and hepatitis C coinfection', Journal of Gastroenterology and Hepatology, vol. 23, pp. 1000 - 1008, http://dx.doi.org/10.1111/j.1440-1746.2008.05489.x
Day C; White B; Thein H; Doab A; Dore G; Bates A; Holden J; Maher L, 2008, 'Experience of hepatitis C testing among injecting drug users in Sydney, Australia', AIDS Care - Psychological and Socio - Medical Aspects of AIDS/HIV, vol. 20, pp. 116 - 123, http://dx.doi.org/10.1080/09540120701426524
Nguyen VT; Law MG; Dore GJ, 2008, 'An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025', Liver International, vol. 28, pp. 525 - 531, http://dx.doi.org/10.1111/j.1478-3231.2007.01646.x
Thein H; Yi Q; Dore GJ; Krahn M, 2008, 'Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis', AIDS, vol. 22, pp. 1979 - 1991, http://dx.doi.org/10.1097/QAD.0b013e32830e6d51
Thein H; Yi Q; Dore GJ; Krahn M, 2008, 'Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression', Hepatology, vol. 48, pp. 418 - 431, http://dx.doi.org/10.1002/hep.22375
Dore GJ; Haber P, 2008, 'Tell me it ain¿t so: Patient-to-patient transmission of hepatitis C in an endoscopy clinic.', Hepatology, vol. 48, pp. 1333 - 1335, http://dx.doi.org/10.1002/hep.22595
Roberts S; Cooksley G; Dore GJ; Robson RA; Shaw DW; Berns H; Hill G; Klumpp K; Najera I; Washington C, 2008, 'Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C', Hepatology, vol. 48, pp. 398 - 406, http://dx.doi.org/10.1002/hep.22321
Crawford DHG; Roberts S; Weltman M; Cheng WSC; Sievert W; McCaughan G; Desmond P; Alston AW; DePamphilis J; Marks P; Dore GJ, 2008, '779 BASELINE FACTORS ASSOCIATED WITH RAPID AND EARLY VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS TREATED WITH INDUCTION DOSING OF PEGYLATED INTERFERON: THE CHARIOT STUDY', Journal of Hepatology, vol. 48, pp. S290 - S291, http://dx.doi.org/10.1016/s0168-8278(08)60781-3
Matthews GV; Seaberg E; Dore GJ; Lewin SR; Bowden S; Sasadeuz J; Marks P; Hoy J; Locarnini S; Thio CL, 2007, 'Combination of HBV-active antiretroviral therapy influences hbv virological suppression in an international cohort of 120 HIVHBV coinfected individuals', JOURNAL OF HEPATOLOGY, vol. 46, pp. S194 - S194, http://dx.doi.org/10.1016/S0168-8278(07)62108-4
Nguyen VT; McLaws M; Dore GJ, 2007, 'Highly endemic hepatitis B infection in rural Vietnam', Journal of Gastroenterology and Hepatology, vol. 22, pp. 2093 - 2100
Dore GJ; Hellard M; Matthews G; Haber PS; Shaw D; Yeung B; Petoumenos K; Van Beek IA; Mccaughan GW; Pan Y; Ffrench R; Rowlinson W; Lloyd AR; Kaldor JM, 2007, 'Treatment of recently acquired hepatitis C infection in injecting drug users: Preliminary results from the Australian trial in acute hepatitis C (ATAHC)', Hepatology, vol. 46, pp. 358A - 358A
Razali K; Thein H; Bell J; Cooper-Stanbury M; Dolan K; Dore G; George J; Kaldor J; Karvelas M; Li J; Maher L; McGregor S; Hellard M; Poeder F; Quaine J; Stewart K; Tyrrell H; Weltman M; Westcott O; Wodak A; Law M, 2007, 'Modelling the hepatitis C virus epidemic in Australia', Drug and Alcohol Dependence, vol. 91, pp. 228 - 235, http://dx.doi.org/10.1016/j.drugalcdep.2007.05.026
Zhou J; Dore GJ; Zhang F; Lim P; Chen Y, 2007, 'Hepatitis B and C virus coinfection in the TREAT asia HIV observational database', Journal of Gastroenterology and Hepatology, vol. 22, pp. 1510 - 1518, http://dx.doi.org/10.1111/j.1440-1746.2007.05062.x
Dore GJ; Torriani F; Rodriguez-Torres M; Brau N; Sulkowski M; Sola Lamoglia R; Clumeck N; Mendes-Correa M; Nelson M; Godofsky E; Dieterich D; Yetzer E; Lissen E; Cooper DA, 2007, 'Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection', AIDS, vol. 21, pp. 1555 - 1559, http://dx.doi.org/10.1097/QAD.0b013e328216f2c7
Thein H; Maruff P; Krahn M; Kaldor JM; Koorey D; Brew BJ; Dore GJ, 2007, 'Improved cognitive function as a consequence of hepatitis C virus treatment', HIV Medicine, vol. 8, pp. 520 - 528, http://dx.doi.org/10.1111/j.1468-1293.2007.00505.x
Thein H; Maruff P; Krahn M; Kaldor JM; Koorey D; Brew BJ; Dore GJ, 2007, 'Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment', HIV Medicine, vol. 8, pp. 192 - 202, http://dx.doi.org/10.1111/j.1468-1293.2007.00452.x
Matthews G; Hellard M; Kaldor JM; Lloyd AR; Dore GJ, 2007, 'Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al', AIDS, vol. 21, pp. 2112 - 2113, http://dx.doi.org/10.1097/QAD.0b013e3282ef3873
Nguyen O; Dore GJ; Kaldor JM; Hellard M, 2007, 'Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study', International Journal of Drug Policy, vol. 18, pp. 447 - 451, http://dx.doi.org/10.1016/j.drugpo.2007.01.007
Micallef JM; Macdonald V; Jauncey ME; Amin J; Rawlinson WD; Van Beek IA; Kaldor JM; White PA; Dore GJ, 2007, 'High Incidence of hepatitis C virus reinfection within a cohort of injecting drug users', Journal of Viral Hepatitis, vol. 14, pp. 413 - 418, http://dx.doi.org/10.1111/j.1365-2893.2006.00812.x
Amin J; Law MG; Micallef JM; Jauncey ME; Van Beek IA; Kaldor JM; Dore GJ, 2007, 'Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users', Epidemiology and Infection, vol. 135, pp. 144 - 150, http://dx.doi.org/10.1017/S0950268806006388
Amin J; O Connell DL; Bartlett M; Tracey E; Kaldor JM; Law MG; Dore GJ, 2007, 'Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study', Australian and New Zealand Journal of Public Health, vol. 31, pp. 475 - 482, http://dx.doi.org/10.1111/j.1753-6405.2007.00121.x
Hallinan R; Byrne AP; Dore GJ, 2007, 'Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction', Drug and Alcohol Review, vol. 26, pp. 437 - 443, http://dx.doi.org/10.1080/09595230701373933
Dore GJ; Micallef JM, 2007, 'Low incidence of HCV reinfection: Exposure, testing frequency, or protective immunity?', Hepatology, vol. 45, pp. 1330 - 1330, http://dx.doi.org/10.1002/hep.21577
Hallinan R; Byrne AP; Agho K; Dore GJ, 2007, 'Referral for chronic hepatitis C treatment from a drug dependency treatment setting', Drug and Alcohol Dependence, vol. 88, pp. 49 - 53, http://dx.doi.org/10.1016/j.drugalcdep.2006.09.018
Dore GJ, 2007, 'Enhancing hepatitis C treatment uptake and outcomes for injection drug users', Hepatology, vol. 45, pp. 3 - 5, http://dx.doi.org/10.1002/hep.21478
Butler TG; Boonwaat L; Hailstone S; Falconer T; Lems P; Ginley T; Read V; Smith N; Levy MH; Dore GJ; Kaldor JM, 2007, 'The 2004 Australian prison entrants` blood-borne virus and risk behaviour survey', Australian and New Zealand Journal of Public Health, vol. 31, pp. 44 - 50, http://dx.doi.org/10.1111/j.1753-6405.2007.00009.x
Matthews G; Cooper DA; Dore GJ, 2007, 'Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir', Antiviral Therapy, vol. 12, pp. 119 - 122
Macdonald V; Dore GJ; Amin J; Van Beek IA, 2007, 'Predictors of completion of a hepatitis Bvaccination schedule in attendees at a primary health care centre.', Sexual Health, vol. 4, pp. 27 - 30, http://dx.doi.org/10.1071/SH06008
Thein H; Yi Q; Dore GJ; Krahn M, 2007, 'Natural history of hepatitis C virus infection in HIV-infected individuals in the era of HAART: Systematic review and meta-analysis', Hepatology, vol. 46, pp. 840A - 841A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249910401616&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Nguyen VT; McLaws M; Dore GJ, 2007, 'Prevalence and risk factors for hepatitis C infection in rural north Vietnam.', Hepatol Int, vol. 1, pp. 387 - 393, http://dx.doi.org/10.1007/s12072-007-9008-3
Matthews G; Dore GJ, 2007, 'Response to Schmutz et al., `Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapv of hepatitis B in HIV-coinfection`', AIDS, vol. 21, pp. 777 - 778, http://dx.doi.org/10.1097/QAD.0b013e3280b07774
Revill P; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin S; Dore GJ; Matthews G; Thio C; Locarnini S, 2007, 'Identification of a novel hepatitis B virus precore/core deletion mutant in HIV-1/hepatitis B virus co-infected individuals.', AIDS, vol. 21, pp. 1701 - 1710, http://dx.doi.org/10.1097/QAD.0b013e32826fb305
Amin J; Law MG; Dore G, 2006, 'Mortality in patients with hepatitis B or hepatitis C - Authors' reply', Lancet, vol. 368, pp. 1767, http://dx.doi.org/10.1016/S0140-6736(06)69729-8
Smith BJ; Bauman A; Loveday S; Costello M; Mackie B; Dore GJ; Chen J, 2006, 'Hepatitis C in Australia: impact of a mass media campaign', American Journal of Preventive Medicine, vol. 31, pp. 492 - 498, http://dx.doi.org/10.1016/j.amepre.2006.08.001
Dore GJ; Cooper DA, 2006, 'HAART`s first decade: success brings further challenges', Lancet, vol. 368, pp. 427 - 428, http://dx.doi.org/10.1016/S0140-6736(06)69128-9
Matthews G; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio C, 2006, 'Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy', AIDS, vol. 20, pp. 863 - 870, http://dx.doi.org/10.1097/01.aids.0000218550.85081.59
Amin J; Law MG; Bartlett M; Kaldor JM; Dore GJ, 2006, 'Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study', Lancet, vol. 368, pp. 938 - 945, http://dx.doi.org/10.1016/S0140-6736(06)69374-4
Thein H; Butler T; Krahn M; Rawlinson WD; Levy M; Kaldor JM; Dore GJ; Butler , 2006, 'The effect of hepatitis C virus infection on health-related quality of life in prisoners', Journal of Urban Health - Bulletin of the New York Academy of Medicine, vol. 83, pp. 275 - 288, http://dx.doi.org/10.1007/s11524-005-9015-4
Micallef JM; Kaldor JM; Dore GJ, 2006, 'Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies', Journal of Viral Hepatitis, vol. 13, pp. 34 - 41, http://dx.doi.org/10.1111/j.1365-2893.2005.00651.x
Dore GJ; Guan R; Jafri SM; Sarin S; Keeffe E, 2006, 'Management of chronic hepatitis B in challenging patient populations.', Liver International, vol. 26, pp. 38 - 46, http://dx.doi.org/10.1111/j.1478-3231.2006.01375.x
Amin J; Dore GJ; O Connell DL; Bartlett M; Tracey E; Kaldor JM; Law MG, 2006, 'Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study', Journal of Hepatology, vol. 45, pp. 197 - 203, http://dx.doi.org/10.1016/j.jhep.2006.02.014
Roberts S; Cooksley G; Dore GJ; Robson RA; Shaw DW; Berns H; Brandl M; Fettner S; Hill G; Ipe D; Klumpp K; Mannino M; O Mara E; Tu Y; Washington C, 2006, 'Results of a phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients', Hepatology, vol. 44, pp. 692A - 692A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000241362302442&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Doab AE; Treloar C; Dore GJ, 2005, 'Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia', Clinical Infectious Diseases, vol. 40, pp. S313 - S320, http://dx.doi.org/10.1086/427446
Jin F; Prestage G; Kippax SC; Kaldor JM; Dore GJ; Grulich AE, 2005, 'Prevalence and risk factors of hepatitis C in HIV-negative homosexual men in Sydney, Australia', Australian and New Zealand Journal of Public Health, vol. 29, pp. 536 - 539, http://dx.doi.org/10.1111/j.1467-842X.2005.tb00246.x
Duncombe CJ; Kerr SJ; Ruxrungtham K; Dore GJ; Law MG; Emery S; Lange J; Phanuphak P; Cooper DA, 2005, 'HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting', AIDS, vol. 19, pp. 169 - 178, http://dx.doi.org/10.1097/00002030-200501280-00009
Matthews G; Kronborg I; Dore GJ, 2005, 'Treatment for hepatitis C virus infection among current injection drug users in Australia', Clinical Infectious Diseases, vol. 40, pp. S325 - S329, http://dx.doi.org/10.1086/427448
Thein H; Krahn M; Kaldor JM; Dore GJ, 2005, 'Estimation of utilities for chronic hepatitis C from SF-36 scores', American Journal of Gastroenterology, vol. 100, pp. 643 - 651, http://dx.doi.org/10.1111/j.1572-0241.2005.40976.x
Hallinan R; Byrne A; Amin J; Dore GJ, 2005, 'Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy', Journal of Gastroenterology and Hepatology, vol. 20, pp. 1082 - 1086, http://dx.doi.org/10.1111/j.1440-1746.2005.03882.x
Dore GJ; Thomas DL, 2005, 'Management and treatment of injection drug users with hepatitis C virus(HCV) infection and HCV/human immunodeficiency virus coinfection', Seminars in Liver Disease, vol. 25, pp. 18 - 32, http://dx.doi.org/10.1055/s-2005-864779
Stoove M; Gifford S; Dore GJ, 2005, 'The impact of injecting drug use status on hepatitis C-related referral and treatment', Drug and Alcohol Dependence, vol. 77, pp. 81 - 86, http://dx.doi.org/10.1016/j.drugalcdep.2004.07.002
Amin J; Law MG; O Connell DL; Bartlett M; Tracey E; Kaldor JM; Dore GJ, 2005, 'Cancer incidence in people with hepatitis B or C infection: A population based cohort study', Journal of Hepatology, vol. 42, pp. 88 - 88, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000229024000228&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Dore GJ, 2004, 'Editorial comment: Triple infection with HIV and hepatitis B and C viruses - Lesson in combination therapy', AIDS Reader, vol. 14, pp. 392
Dore GJ; Cooper DA; Pozniak A; DeJesus E; Zhong L; Miller MD; Lu B; Cheng A, 2004, 'Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus', Journal of Infectious Diseases, vol. 189, pp. 1185 - 1192, http://dx.doi.org/10.1086/380398
Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA; Dore GJ, 2004, 'Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort', AIDS, vol. 18, pp. 1169 - 1177, http://dx.doi.org/10.1097/00002030-200405210-00010
Amin J; Kaye M; Skidmore S; Pillay D; Cooper DA; Dore GJ, 2004, 'HIV and hepatitis C coinfection within the CAESAR study', HIV Medicine, vol. 5, pp. 174 - 179, http://dx.doi.org/10.1111/j.1468-1293.2004.00207.x
O Sullivan BG; Gidding H; Law MG; Kaldor JM; Gilbert GL; Dore GJ, 2004, 'Estimates of chronic hepatitis B virus infection in Australia, 2000', Australian and New Zealand Journal of Public Health, vol. 28, pp. 212 - 216, http://dx.doi.org/10.1111/j.1467-842X.2004.tb00697.x
Jauncey ME; Micallef JM; Gilmour S; Amin J; White PA; Rawlinson WD; Kaldor JM; Van Beek IA; Dore GJ, 2004, 'Clearance of hepatitis C virus after newly acquired infection ininjection drug users', Journal of Infectious Diseases, vol. 190, pp. 1270 - 1274, http://dx.doi.org/10.1086/423943
Robotin M; Copland J; Tallis G; Coleman D; Giele C; Carter L; Spencer J; Kaldor JM; Dore GJ, 2004, 'Surveillance for newly acquired hepatitis C in Australia', Journal of Gastroenterology and Hepatology, vol. 19, pp. 283 - 288, http://dx.doi.org/10.1111/j.1440-1746.2003.03270.x
Amin J; Gidding HF; Gilbert GL; Backhouse J; Kaldor JM; Dore GJ; Burgess MA, 2004, 'Hepatitis C prevalence - a nationwide serosurvey', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, vol. 28, pp. 517 - 521
Hallinan R; Amin J; Dore GJ, 2004, 'Hepatitis C virus incidence among injecting drug users on opioid replacement therapy', Australian and New Zealand Journal of Public Health, vol. 28, pp. 576 - 578, http://dx.doi.org/10.1111/j.1467-842X.2004.tb00050.x
Rerksuppaphol S; Hardikar W; Dore GJ, 2004, 'Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children', Journal of Gastroenterology and Hepatology, vol. 19, pp. 1357 - 1362, http://dx.doi.org/10.1111/j.1440-1746.2004.03463.x
Hutin Y; Kitler M; Dore GJ; Perz J; Armstrong G; Dusheiko G; Ishibashi H; Grob P; Kew M; Marcellin P; Seeff L; Beutels P; Nelson CJ; Stein C; Zurn P; Clifford G; Vranckx R; Alberti A; Hallaj Z; Hadler S; Lavanchy D, 2004, 'Global burden of disease (GBD) for hepatitis C', Journal of Clinical Pharmacology, vol. 44, pp. 20 - 29, http://dx.doi.org/10.1177/0091270003258669
Qasabian R; Meagher AP; Lee RW; Dore GJ; Keogh AM, 2004, 'Severe diverticulitis after heart, lung, and heart-lung transplantation', Journal of Heart and Lung Transplantation, vol. 23, pp. 845 - 849, http://dx.doi.org/10.1016/j.healun.2003.07.019
O'Sullivan BG; Gidding HF; Law M; Kaldor JM; Gilbert GL; Dore GJ, 2004, 'Estimates of chronic hepatitis B virus infection in Australia, 2000', Australian and New Zealand Journal of Public Health, vol. 28, pp. 212 - 216, http://dx.doi.org/10.1111/j.1467-842x.2004.tb00477.x
Matthews G; Dore G, 2003, 'Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: We must target the virus or liver fibrosis?' [3]', AIDS, vol. 17, pp. 2675 - 2676
Bernstein D; Dore GJ; Thein HH; Salomon JA; Goldie SJ, 2003, 'Cost-effectiveness of Treatment for Chronic Hepatitis C Infection [2] (multiple letters)', JAMA, vol. 290, pp. 1993 - 1994, http://dx.doi.org/10.1001/jama.290.15.1993-a
Dore GJ; Thein HH, 2003, 'Cost-effectiveness of treatment for chronic hepatitis C infection', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 290, pp. 1993 - 1993, http://dx.doi.org/10.1001/jama.290.15.1993-b
Hiransuthikul N; Hanvanich M; Dore GJ; Mokkhawes T; Li Y; Perriens J; Kaldor JM, 2003, 'Factors associated with tuberculin skin test reactivity among HIV-infected people in Bangkok', Southeast Asian Journal of Tropical Medicine and Public Health, vol. 34, pp. 804 - 809
Dore GJ; MacDonald M; Law MG; Kaldor JM, 2003, 'Epidemiology of hepatitis C virus infection in Australia.', Australian family physician, vol. 32, pp. 796 - 798
Thein HH; Haber PS; Dore GJ, 2003, 'Quality of life of women living with hepatitis C', Journal of Gastroenterology and Hepatology (Australia), vol. 18, pp. 1329 - 1331, http://dx.doi.org/10.1046/j.1440-1746.2003.03216.x
Dore G, 2003, 'Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.', Journal of HIV therapy, vol. 8, pp. 96 - 100
Dore GJ, 2003, 'Cost-effectiveness of treatment for chronic hepatitis C infection', Journal of the American Medical Association, vol. 290, pp. 1933 - 1934
Thein H; Haber P; Dore GJ, 2003, 'Quality of life among women with hepatitis C (editorial)', Journal of Gastroenterology and Hepatology, vol. 18, pp. 1329 - 1331
Thompson S; Boughton CR; Dore GJ, 2003, 'The Viral Hepatitis Prevention Board (Australia). Blood-borne viruses and their survival in the environment: Is public concern about community needlestick exposures justified?', Australian and New Zealand Journal of Public Health, vol. 27, pp. 602 - 607
Matthews G; Dore GJ, 2003, 'Treatment of chronic hepatitis c virus infection: we must target the virus or liver fibrosis (letter)?', AIDS, vol. 17, pp. 2675 - 2676
McDonald AM; Li Y; Dore GJ; Ree H; Kaldor JM, 2003, 'Late HIV presentation among AIDS cases in Australia, 1992-2001', Australian and New Zealand Journal of Public Health, vol. 27, pp. 608 - 613, http://dx.doi.org/10.1111/j.1467-842X.2003.tb00607.x
Dore GJ; McDonald AM; Li Y; Kaldor JM; Brew BJ, 2003, 'Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy', AIDS, vol. 17, pp. 1539 - 1545, http://dx.doi.org/10.1097/00002030-200307040-00015
Lincoln DW; Petoumenos K; Dore GJ, 2003, 'HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy', HIV Medicine, vol. 4, pp. 241 - 249, http://dx.doi.org/10.1046/j.1468-1293.2003.00152.x
Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA, 2003, 'Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001', AIDS, vol. 17, pp. 2191 - 2199, http://dx.doi.org/10.1097/00002030-200310170-00007
Spencer J; Tibbits D; Tippet C; Mead C; Kaldor JM; Dore GJ, 2003, 'Review of antenatal testing policies and pratice for HIV and hepatitis C infection', Australian and New Zealand Journal of Public Health, vol. 27, pp. 614 - 619, http://dx.doi.org/10.1111/j.1467-842X.2003.tb00608.x
Dore GJ; Freeman A; Law MG; Kaldor JM, 2003, 'Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings', Antiviral Therapy, vol. 8, pp. 365 - 372
Freeman A; Law MG; Kaldor JM; Dore GJ, 2003, 'Predicting progression to cirrhosis in chronic hepatitis C virus infection', Journal of Viral Hepatitis, vol. 10, pp. 285 - 293, http://dx.doi.org/10.1046/j.1365-2893.2003.00436.x
Dore GJ; Law MG; MacDonald MA; Kaldor JM, 2003, 'Epidemiology of hepatitis C virus infection in Australia', Journal of Clinical Virology, vol. 26, pp. 171 - 184, http://dx.doi.org/10.1016/S1386-6532(02)00116-6
Law MG; Dore GJ; Bath N; Thompson S; Crofts N; Dolan K; Giles W; Gow P; Kaldor JM; Loveday S; Powell E; Spencer J; Wodak AD, 2003, 'Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001', International Journal of Epidemiology, vol. 32, pp. 717 - 724, http://dx.doi.org/10.1093/ije/dyg101
Thompson S; Boughton CR; Dore GJ, 2003, 'Blood-borne viruses and their survival in the environment: is publicconcern about community needlestick exposures justified?', Australian and New Zealand Journal of Public Health, vol. 27, pp. 602 - 607, http://dx.doi.org/10.1111/j.1467-842X.2003.tb00606.x
Thein H; Denoe M; Van Beek IA; Dore GJ; MacDonald MA, 2003, 'Injecting behaviour of injecting drug users at needle and syringe programs and pharmacies in Australia', International Journal of Drug Policy, vol. 14, pp. 425 - 430, http://dx.doi.org/10.1016/j.drugpo.2003.06.001
Hellard M; Hocking J; Willis JE; Dore GJ; Fairley CK, 2003, 'Risk factors leading to Cryptosporidium infection in men who have sex with men', Sexually Transmitted Infections, vol. 79, pp. 412 - 414, http://dx.doi.org/10.1136/sti.79.5.412
Dore GJ, 2003, 'Clinical management of HIV/viral Hepatitis coinfection', Journal of Clinical Virology, vol. 28, pp. S43 - S43, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000187711900063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
MacDonald MA; Law MG; Kaldor JM; Hales J; Dore GJ, 2003, 'Effectiveness of needle and syringe programmes for preventing HIV transmission', International Journal of Drug Policy, vol. 14, pp. 353 - 357, http://dx.doi.org/10.1016/S0955-3959(03)00133-6
MICALLEF J; JAUNCEY M; AMIN J; RAWLINSON W; GILMOUR S; VANBEEK I; KALDOR J; WHITE P; DORE G, 2003, '229 Hepatitis C virus reinfection within a cohort of injecting drug users', Hepatology, vol. 38, pp. 266 - 266, http://dx.doi.org/10.1016/s0270-9139(03)80272-0
Dore GJ; Freeman AJ; Kaldor JM; Post JJ; Harvey CE; Ffrench RA; Lloyd AR; Mehta SH; Cox AL; Strathdee SA; Vlahov D; Thomas DL, 2002, 'Immunity against hepatitis C virus infection [2] (multiple letters)', Lancet, vol. 360, pp. 1019 - 1020, http://dx.doi.org/10.1016/s0140-6736(02)11102-0
McDonald AM; Dore GJ; Grulich AE; Law MG; Prestage G; Smith DE, 2002, 'Epidemiological and social research finds at the 14th International AIDS Conference', Australian HIV Surveillance Report, vol. 18, pp. 1 - 8
Pett SL; Dore GJ; Fielden R; Cooper DA, 2002, 'Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1', AIDS, vol. 16, pp. 2364 - 2365, http://dx.doi.org/10.1097/00002030-200211220-00029
Danta M; Dore GJ; Hennessy L; Li Y; Vickers CR; Harley H; Ngu M; Reed W; Desmond PV; Sievert W; Farrell G; Kaldor JM; Batey RG, 2002, 'Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection', Medical Journal of Australia, vol. 177, pp. 240 - 245
Dore GJ; Freeman A; Law MG; Kaldor JM, 2002, 'Is severe liver disease a common outcome for people with chronic hepatitis C?', Journal of Gastroenterology and Hepatology, vol. 17, pp. 423 - 430, http://dx.doi.org/10.1046/j.1440-1746.2002.02730.x
Talawat S; Dore GJ; Le Coeur S; Lallemant M, 2002, 'Infant feeding practices and attitudes among women with HIV infection in northern Thailand', AIDS Care - Psychological and Socio - Medical Aspects of AIDS/HIV, vol. 14, pp. 625 - 631, http://dx.doi.org/10.1080/0954012021000005452
Spencer J; Dore GJ; Robotin M; Correll PK; Kaldor JM, 2002, 'Outcomes from the first two years of the Australian Hepatitis surveillance strategy', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, vol. 26, pp. 14 - 22
Dore GJ; Li Y; McDonald AM; Ree H; Kaldor JM, 2002, 'Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 29, pp. 388 - 395, http://dx.doi.org/10.1097/00126334-200204010-00010
Dore GJ; Freeman A; Kaldor JM, 2002, '. Immunity against hepatitis C virus infection', Lancet, vol. 360, pp. 1019 - 1020
Law MG; Dore GJ; Kaldor JM, 2001, 'Projecting severe sequelae of injection-related hepatitis C virus epidemic in UK by SM Bird, DJ Goldberg and SJ Hutchinson', Journal of Epidemiology and Biostatistics, vol. 6, pp. 279 - 281, http://dx.doi.org/10.1080/135952201317080689
Dore GJ; Cooper DA, 2001, 'Bridging the divide: Global inequities in access to HIV/AIDS therapy', Medical Journal of Australia, vol. 175, pp. 570 - 572, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143729.x
Dore GJ; Li Y; McDonald AM; Kaldor JM, 2001, 'Spectrum of AIDS-defining illnesses in Australia, 1992 to 1998: Influence of country/region of birth', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 26, pp. 283 - 290, http://dx.doi.org/10.1097/00126334-200103010-00012
Dore GJ; Cooper DA, 2001, 'The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses', Current Opinion in Infectious Diseases, vol. 14, pp. 749 - 755, http://dx.doi.org/10.1097/00001432-200112000-00014
Freeman A; Dore GJ; Law MG; Thorpe M; Von Overbeck J; Lloyd AR; Marinos G; Kaldor JM, 2001, 'Estimating progression to cirrhosis in chronic hepatitis C virus infection.', Hepatology, vol. 34, pp. 809 - 816, http://dx.doi.org/10.1053/jhep.2001.27831
Dore GJ; Kaldor JM; Leruez-Ville M; Rouzioux C; Chaix ML, 2000, 'Detection of HCV RNA in semen [1] (multiple letters)', Lancet, vol. 356, pp. 1520, http://dx.doi.org/10.1016/S0140-6736(00)02890-7
Dore GJ; Kaldor JM, 2000, 'Detection of HCV RNA in semen', LANCET, vol. 356, pp. 1520 - 1520, http://dx.doi.org/10.1016/S0140-6736(00)02890-7
Li Y; McDonald AM; Dore GJ; Kaldor JM, 2000, 'Improving survival following AIDS in Australia, 1991-1996. National HIV Surveillance Committee.', AIDS, vol. 14, pp. 2349 - 2354, http://dx.doi.org/10.1097/00002030-200010200-00016
Freeman AJ; Dore GJ; Law MG; Thorpe M; Von Overbeck J; Lloyd AR; Marinos G; Kaldor JM, 2000, 'The natural history of chronic hepatitis C: A systematic review', HEPATOLOGY, vol. 32, pp. 422A - 422A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000089622401038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Guthrie JA; Dore GJ; McDonald AM; Kaldor JM, 2000, 'HIV and AIDS in aboriginal and Torres Strait Islander Australians: 1992-1998. The National HIV Surveillance Committee.', Med J Aust, vol. 172, pp. 266 - 269, https://www.ncbi.nlm.nih.gov/pubmed/10860091
Kaldor JM; Dore GJ; Correll PKL, 2000, 'Public health challenges in hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), vol. 15, http://dx.doi.org/10.1046/j.1440-1746.2000.02134.x
Dore GJ; Kaldor JM, 2000, 'Detection of HCV RNA in semen (letter)', Lancet, pp. 1520 - 1520
Kaldor JM; Dore GJ; Correll PK, 2000, 'Towards control of hepatitis C in the Asia-Pacific region ¿ Public health challenges in hepatitis C virus infection', Journal of Gastroenterology and Hepatology, vol. 15, pp. E83 - E90
Dore GJ, 2000, 'Sexual transmission of hepatitis C: what is the evidence?', Australian Hepatitis Chronicle, pp. 2 - 5
Dore GJ; Grulich AE; Prestage G, 2000, 'Epidemiological and social research findings reported at the 13th World AIDS Conference', Australian HIV Surveillance Report, vol. 16, pp. 1 - 6
Law MG; Roberts S; Dore GJ; Kaldor JM, 2000, 'Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality', Medical Journal of Australia, vol. 173, pp. 403 - 405
Li Y; McDonald AM; Dore GJ; Kaldor JM; For TNHS, 2000, 'Improving survival following AIDS in Australia, 1991-1996', AIDS, vol. 14, pp. 2349 - 2354, http://dx.doi.org/10.1097/00002030-200010200-00016
Grulich AE; Dore GJ; Brew BJ, 2000, 'Human herpesvirus 8 and protection from AIDS dementia complex', Herpes, vol. 7, pp. 38 - 40
Dore GJ, 2000, 'Infectious diseases in the 21st century: are we entering the hot-zone?', Australian Family Physician, vol. 29, pp. 627 - 630
Dore GJ; Brew BJ, 2000, 'Response to Eberly et al., Kaposi¿s sarcoma and central nervous system disease: a real association or an artifact of the control group? (letter)', AIDS, vol. 14, pp. 2631 - 2632, http://dx.doi.org/10.1097/00002030-200011100-00037
Brew BJ; Dore GJ, 2000, 'Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy (letter)', Neurology, vol. 55, pp. 1424 - 1424, http://dx.doi.org/10.1212/WNL.55.9.1424
Wilkinson DL; Dore GJ, 2000, 'An unbridgeable gap? Comparing the HIV/AIDS epidemics in Australia and sub-Saharan Africa', Australian and New Zealand Journal of Public Health, vol. 24, pp. 276 - 280, http://dx.doi.org/10.1111/j.1467-842X.2000.tb01568.x
Guthrie J; Dore GJ; McDonald AM; Kaldor JM; For TNHS, 2000, 'HIV and AIDS in Aboriginal and Torres Strait Islander Australians:1992-1998', Medical Journal of Australia, vol. 172, pp. 266 - 269
Lurie P; Wolfe SM; McNeill PM; Dore GJ, 1999, 'Should research ethics change at the border? (multiple letters) [6]', Medical Journal of Australia, vol. 171, pp. 167 - 168, http://dx.doi.org/10.5694/j.1326-5377.1999.tb123586.x
Dore GJ; Pritchard-Jones J; Fisher D; Law MG, 1999, 'Who's at risk: risk factors for HCV infection in Australia', Australian Family Physician, pp. 8 - 13
Dore GJ; Correll PK; Li Y; Kaldor JM; Cooper DA; Brew BJ, 1999, 'Changes to AIDS dementia complex in the era of highly active antiretroviral therapy', AIDS, vol. 13, pp. 1249 - 1253, http://dx.doi.org/10.1097/00002030-199907090-00015
Dore GJ; Cooper DA; Barrett C; Goh L; Thakrar B; Atkins M, 1999, 'Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR)', Journal of Infectious Diseases, vol. 180, pp. 607 - 613, http://dx.doi.org/10.1086/314942
Mcneil PM; Dore GJ, 1999, 'Should research ethics change at the border?', Medical Journal of Australia, vol. 171, pp. 168 - (letter), http://dx.doi.org/10.5694/j.1326-5377.1999.tb123587.x
Dore GJ; Law MG; Kaldor JM, 1999, 'Prevalence of hepatitis C virus infection in the United States', New England Journal of Medicine, vol. 341, pp. 2093 - 2094 (lett
Wettstein AR; Dore G; Murphy C; Edwards PD, 1998, 'HIV related cholangiopathy (HIVRC): Is endoscopic biliary sphincterotomy (EBS) an effective therapy?', Gastrointestinal Endoscopy, vol. 47
McNeill PM, 1998, 'Should research ethics change at the border?', Medical Journal of Australia, vol. 169, pp. 509 - 510, http://dx.doi.org/10.5694/j.1326-5377.1998.tb123394.x
Collignon P; Dore GJ; Li Y; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality rates (multiple letters) [3]', Medical Journal of Australia, vol. 169, http://dx.doi.org/10.5694/j.1326-5377.1998.tb126845.x
Dore GJ; Kaldor JM; McCaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C - Summary vertical transmission rates may be misleading - Reply', BRITISH MEDICAL JOURNAL, vol. 316, pp. 554 - 554, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072097400048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Thomas S; Hall A; Newell ML; Dore GJ; Kaldor JM; McCaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C (multiple letters) [5]', British Medical Journal, vol. 316, pp. 553 - 554
Hira SK; Dore GJ; Sirisanthana T, 1998, 'Clinical spectrum of HIV/AIDS in the Asia-Pacific region.', AIDS (London, England), vol. 12 Suppl B
Dore GJ; Kaldor JM; Mccaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C', British Medical Journal: International, pp. 553 - 554
Dore GJ, 1998, 'Report from the 4th International Conference on AIDS in Asia and the Pacific', Noah's Arc
Crofts JN; Dore GJ; Kaldor JM; Law MG; Wodak AD; Et A, 1998, 'Estimates and projections of the hepatitis C virus epidemic in Australia', ION Meeting Proceedings
McDonald AM; French R; Dore GJ; Hamernik E; Kippax SC; Ashton LJ, 1998, 'Epidemiological and social research findings reported at the 12th World AIDS Conference, Geneva 1998', Australian HIV Surveillance Report, vol. 14, pp. 1 - 9
Dore GJ; Li YW; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality in Australia, 1979-1994', Medical Journal of Australia, vol. 168, pp. 601 - 604
Dore GJ; Brown TA; Tarantola D; Kaldor JM, 1998, 'HIV and AIDS in the Asia-Pacific region: an epidemiological overview', AIDS, vol. 12, pp. S1 - S10
Dore GJ, 1998, 'Chronic hepatitis C infection: a disease ideally suited to management in the primary care setting', Australian Family Physician, vol. 27, pp. 791 - 793
Dore GJ; Grulich AE; Law MG; Brew BJ; Kaldor JM, 1998, 'Kaposi¿s sarcoma and protection from AIDS dementia complex', AIDS, vol. 12, pp. 2354 - 2355
Dore GJ; Kaldor JM, 1998, 'Sexually transmissible diseases surveillance in Australia: towards a coordinated national system', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, vol. 22, pp. 49 - 52
Van Beek IA; Dwyer RG; Dore GJ; Luo K; Kaldor JM, 1998, 'Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study', British Medical Journal: International, vol. 317, pp. 433 - 437
Dore GJ; Li YW; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality rates', Medical Journal of Australia, vol. 169, pp. 444 - 445, http://dx.doi.org/10.5694/j.1326-5377.1998.tb126846.x
Aguado JM; Pulido F; Dore GJ; Law MG; Kaldor JM; Gordin F; Matts J, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection [4] (multiple letters)', New England Journal of Medicine, vol. 337, pp. 1696 - 1697, http://dx.doi.org/10.1056/NEJM199712043372316
Dore GJ; Law MG; Kaldor JM, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.', The New England journal of medicine, vol. 337, pp. 1697
Dore GJ; Law MG; Brew BJ, 1997, 'Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection', Journal of Neuro-AIDS, vol. 1, pp. 59 - 69, http://dx.doi.org/10.1300/J128v01n04_06
Dore GJ; Law MG; Kaldor JM, 1997, 'A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis', New England Journal of Medicine, pp. 315 - 320
Dore GJ; Hoy JF; Mallal SS; Li YW; Mijch AM; French MA; Cooper DA; Kaldor JM, 1997, 'Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS Cohort', Journal of acquired immune deficiency syndrome and human retrovirology, vol. 16, pp. 39 - 43, http://dx.doi.org/10.1097/00042560-199709010-00006
Gray JA; Dore GJ; Li Y; Supawitkul S; Effler P; Kaldor JM, 1997, 'HIV-1 infection among female commercial sex workers in rural Thailand', AIDS, vol. 11, pp. 89 - 94, http://dx.doi.org/10.1097/00002030-199701000-00013
Dore GJ; Kaldor JM; Mccaughan GW, 1997, 'Systematic review of role of polymerase chain reaction in defining infectiousness among people with hepatitis C virus', British Medical Journal: Clinical Research, vol. 315, pp. 333 - 337
Gray JA; Dore GJ; Li Y; Supawitkul S; Effler P; Kaldor JM, 1997, '"HIV-1 Infection among Female Commercial Sex Workers in Rural Thailand."', Studies in Family Planning, vol. 28, pp. 168 - 168, http://dx.doi.org/10.2307/2138125
Dore GJ; Kaldor JM; Ungchusak K; Mertens TE, 1996, 'Epidemiology of HIV and AIDS in the Asia-Pacific region', Medical Journal of Australia, vol. 165, pp. 494 - 498, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138615.x
Dore GJ; Kaldor JM; Ungchusak K; Mertens TE, 1996, 'Managing HIV .9. HIV in Asia and the Pacific - Epidemiology of HIV and AIDS in the Asia-Pacific region', MEDICAL JOURNAL OF AUSTRALIA, vol. 165, pp. 494 - 498, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138615.x
Dore GJ; Li YW; Mallal SA; Hoy JF; Mijch AM; French MA; Cooper DA; Kaldor JM; Grulich AE, 1996, 'Declining incidence and later occurrence of Kaposi`s sarcoma among people with AIDS in Australia: the Australian AIDS cohort', AIDS, vol. 10, pp. 1401 - 1406, http://dx.doi.org/10.1097/00002030-199610000-00013
Couldwell D; Dore GJ; Harkness JL; Marriott D; Cooper DA; Edwards RJ; Li YW; Kaldor JM, 1996, 'Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room', AIDS, vol. 10, pp. 521 - 525, http://dx.doi.org/10.1097/00002030-199605000-00011
Law MG; Dore GJ; McDonald AM; Kaldor JM, 1996, 'The use of back-projection to estimate HIV prevalence in pregnant women', Paediatric AIDS and HIV Infection, vol. 7, pp. 331 - 336
Dore GJ; Marriott D; Hing MC; Harkness JL; Field AS, 1995, 'Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with Human Immunodeficiency virus: Response to therapy with Albendazole', Clinical Infectious Diseases, vol. 21, pp. 70 - 76, http://dx.doi.org/10.1093/clinids/21.1.70
Dore GJ; Marriot DJ; Duflou J, 1995, 'Clinico-pathological study of cytomegalovirus infection (CMV) is AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis', Australian and New Zealand Journal of Medicine, vol. 25, pp. 503 - 506, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01495.x
Price O; Dietze PM; Maher L; Dore GJ; Crawford S; Sutherland R; Salom C; Bruno R; Lenton S; Degenhardt L; Peacock A, 2022, 'COVID-19 pandemic experiences of people in Australia who inject drugs: Analysis of illicit drug reporting system interview data 2020-2022', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S115 - S115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J, 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy, WILEY, pp. S146 - S147, http://dx.doi.org/10.1016/j.drugpo.2022.103706
Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Amin J; Christmass M; Dunlop AJ; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Dore GJ; Treloar C; Grebely J, 2021, 'OPIOID OVERDOSE AND NALOXONE ACCESS AMONG PEOPLE WHO RECENTLY USED OPIOIDS OR RECEIVED OPIOID AGONIST TREATMENT IN AUSTRALIA: THE ETHOS ENGAGE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Grebely J; Marshall AD, 2021, '"WE'VE HAD A CIRCUIT BREAKER FOR AN OLD DOGMA OF MORE THAN 20 YEARS": CHANGES TO OPIOID AGONIST TREATMENT SERVICES DURING COVID-19, THE CHOICE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Casey J; MacParland S; Zahoor A; Janssen HLA; Matthews G; Marks P; Grebely J; Dore G; Hansen BE; Kaul R; Chua C; Gehring AJ; Feld JJ, 2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 November 2020 - 16 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000574027002142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Papaluca T; Roberts S; Strasser S; Stuart K; New K; Farrell G; Dore G; Wigg A; Woodward A; Wade A; George J; Sinclair M; McGarity B; Fisher AL; Sawhney R; Wilson M; Valiozis I; Levy M; Tse E; Ahlenstiel G; Haque M; Prewett E; Sievert W; Sood S; O'Beirne J; Thomas J; Hazeldine S; Valaydon Z; Douglas M; Bowden S; O'Keefe J; Holmes J; Thompson A, 2020, 'Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER, pp. S363 - S363, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587001118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Marshall AD; Grebely J; Dore GJ; Treloar C, 2019, 'BARRIERS AND FACILITATORS TO ENGAGING IN HEPATITIS C MANAGEMENT AND DIRECT-ACTING ANTIVIRAL THERAPY AMONG GENERAL PRACTITIONERS AND DRUG AND ALCOHOL SPECIALISTS: THE PRACTITIONER EXPERIENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S9 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Papaluca T; New K; Strasser S; Stuart K; Dore G; Farrell G; George J; Jeffrey G; O'Beirne J; Sinclair M; Wade A; Ahlenstiel G; Hazeldine S; Wigg A; Sheikh K; Woodward A; Weltman M; Valiozis I; Mcgarity B; Fisher L; Levy M; Tse E; Wilson M; Thomas J; Lee A; Sawhney R; Sievert W; Sood S; Cheng W; Roberts S; Thompson A, 2019, 'Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 72 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Artenie AA; Cunningham E; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Applegate TL; Dillon JF; Fraser C; Gane E; Litwin AH; Marks P; Matthews GV; Quiene S; Thurnheer MC; Weltman M; Dore G; Bruneau J; Grebely J, 2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Bajis S; Hajarizadeh B; Marshall A; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing D; Kleman M; Cunningham P; Dore G; Applegate T; Grebely J, 2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S167 - S167, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30546-4
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin N; Mchutchison JG; Brainard D; Treloar C; Lloyd A; Dore G, 2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S187 - S188, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30587-7
Lamoury F; Bajis S; Martinez D; Mowat Y; Jayasinghe I; Martinez M; Cunningham P; Catlett B; Jacka B; Marks P; Grebely J; Cloherty G; Dore G; Applegate T, 2018, 'Evaluation of a hepatitis C virus core antigen assay in dried-blood spots: a cohort study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S317 - S318, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30854-7
Morley KC; Baillie AJ; Dore GJ; Phung N; Fraser I; Furneaux-Bate A; Haber PS, 2017, 'A RANDOMISED CLINICAL TRIAL OF BACLOFEN FOR THE TREATMENT OF ALCOHOL DEPENDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 53 - 53, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500138&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Feld JJ; Wyles D; Sulkowski MS; Ni L; Llewellyn J; Mir H; Sajed N; Stamm LM; Hyland R; McNally J; Brainard D; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C VIRUS INFECTION IN PATIENTS RECEIVING OPIOID SUBSTITUTION THERAPY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 34 - 35, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Luetkemeyer A; Peng C-Y; Iser DM; Gendrano IN; Kelly MM; Huang H-C; Hwang P; Barr E; Robertson M; Platt H, 2017, 'Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B', in HEPATOLOGY, WILEY, DC, Washington, pp. 112A - 113A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089800196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cunningham EB; Hajarizadeh B; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Dore GJ; Lloyd AR; Grebely J, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31370-3
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0
Grebley J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster G; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Alami NN; Zhang Z; Dumas E; Dore GJ, 2017, 'Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S514 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31430-7
Grebely J; Lamoury F; Hajarizadeh B; Mowat Y; Marshall A; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore G; Applegate TL, 2017, 'Field evaluation of Xpert (R) HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S709 - S709, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31900-1
Lubel JS; Pianko S; Thompson A; Strasser S; Dore G; Stuart K; MacQuillan G; Iser D; Mitchell J; Gazzola A; Chivers S; Mishra G; Gow P; George J; Gough J; Tse E; Zekry A; Levy M; Fragomeli V; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Cheng W; Wigg A; Roberts S, 2017, 'Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir plus /- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis -Final results of the REV1TAL study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S521 - S521, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31444-7
Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore G, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, MA, Boston, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson AJ; Iser DM; Gazzola A; Chivers S; Mishra G; Gough J; Strasser SI; Dore G; Stuart KA; George J; Tse E; Zekry A; Levy M; MacQuillan GC; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo SJ; Jones TL; Wade AJ; Roberts SK, 2016, 'Frequency and severity of biochemical abnormalities with paritaprevir/ritonavir/ombitasvir +/- ribavirin in a real-world cohort of HCV Genotype 1 patients - predictors and clinical significance', in HEPATOLOGY, WILEY, MA, Boston, pp. 442A - 442A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802154&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Foster GR; Thompson AJ; Ruane PJ; Borgia SM; Dore G; Workowski K; Hyland RH; Wang J; Svarovskaia ES; Stamm LM; Brainard DM; Subramanian M; McHutchison JG; Berg T; Agarwal K; Conway B; Feld JJ; Willems BE; Roberts SK, 2016, 'A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 135A - 136A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493800259&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson AJ; Iser DM; Gazzola A; Chivers S; Mishra G; Gough J; Strasser SI; Dore G; Stuart KA; George J; Tse E; Zekry A; Levy M; MacQuillan GC; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo SJ; Jones TL; Wade AJ; Roberts SK, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 483A - 484A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ; Altice F; Litwin AH; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Gendrano IN; Huang HC; Chen E; Nguyen BY; Wahl J; Barr E; Robertson R; Platt HL, 2016, 'C-EDGE CO-STAR: Risk of reinfection following successful therapy with elbasvir and grazoprevir in persons who inject drugs (PWID) receiving opioid agonist therapy (OAT)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 70 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ, 2016, 'INTERFERON-FREE HCV THERAPY FOR PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 15 - 15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson A; Iser D; Gazzola A; Chivers S; Mishra G; Gough J; Strasser S; Dore G; Stuart K; George J; Tse E; Zekry A; Levy M; Macquillan G; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Roberts SK, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 77 - 78, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lubel J; Mitchell J; Pianko S; Thompson A; Iser D; Gazzola A; Chivers S; Mishra G; Gough J; Strasser S; Dore G; Stuart K; George J; Tse E; Zekry A; Levy M; Macquillan G; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Roberts SK, 2016, 'Frequency and severity of hyperbilirubinaemia with Viekira Pak in a real-world cohort of HCV genotype 1 patients - Predictors and clinical significance', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 78 - 79, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700140&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Arduino JM; Shibolet O; Litwin AH; Grebeley J; Altice F; Nwankwo C; Mast TC; Jiang Z; Gendrano IN; Platt HL; Dore GJ, 2016, 'C-EDGE CO-STAR: FAVORABLE IMPACT OF ELBASVIR AND GRAZOPREVIR ON HEALTH-RELATED QUALITY OF LIFE IN TREATMENT-NAIVE HCV-INFECTED PERSONS WHO INJECT DRUGS RECEIVING OPIOID AGONIST THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S403 - S404, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00638-3
Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S614 - S614, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7
Dore G; Altice F; Litwin AH; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Gendrano IN; Huang H-C; Chen E; Nguyen B-Y; Wahl J; Barr E; Robertson M; Platt HL, 2016, 'C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR AND GRAZOPREVIR IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOID AGONIST THERAPY (OAT)', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S771 - S771, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01503-8
Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL FOR 12 WEEKS IS WELL TOLERATED AND RESULTS IN HIGH SVR12 RATES IN PEOPLE RECEIVING OPIOID SUBSTITUTION THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S776, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'COMPARING INDIVIDUAL AND POPULATION PREVENTION BENEFITS OF EARLY DIRECT-ACTING ANTIVIRAL TREATMENT FOR HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S464 - S464, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00779-0
Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'ON-TREATMENT ILLICIT DRUG USE DID NOT IMPACT TREATMENT OUTCOME DURING THERAPY WITH LEDIPASVIR-SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN THE PHASE 3 ION-1 STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S777, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800099&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S753 - S754, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
Leroy V; Angus PW; Bronowicki J-P; Dore G; Hezode C; Pianko S; Pol S; Stuart KA; Tse E; McPhee F; Bhore R; Exposito MJJ; Thompson AJ, 2015, 'All-Oral Treatment With Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 Weeks in HCV Genotype (GT) 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+Phase 3 Study', in HEPATOLOGY, WILEY-BLACKWELL, pp. 1380A - 1381A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367013200004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Waziry RK; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G, 2015, 'Trends in end-stage liver disease among people notified with HBV or HCV in New South Wales, Australia: 2000-2014', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1121A - 1121A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375404114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore G; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Grebely J; Howe AY; Nguyen B-YT; Wahl J; Barr E; Robertson M; Platt HL, 2015, 'C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 227A - 228A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375400041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S1084 - S1085, presented at 46th Annual Digestive Disease Week (DDW), DC, Washington, 16 May 2015 - 19 May 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000360120800122&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Plasma Interferon-gamma-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S1087 - S1088, presented at 46th Annual Digestive Disease Week (DDW), DC, Washington, 16 May 2015 - 19 May 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000360120800131&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore G; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw D; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'MALACHITE-II: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN PEGINTERFERON/RIBAVIRIN TREATMENT-EXPERIENCED ADULTS WITH HCV GENOTYPE 1', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S656 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31049-7
Hickman M; Martin N; Vickerman P; David G; Hutchinson S; Martin T; Dore G; Grebeley J; Miners A; Foster C, 2015, 'HOW SHOULD SCALE UP OF HCV ANTIVIRAL TREATMENT BE PRIORITIZED? A COST-EFFECTIVENESS ANALYSIS INCLUDING INDIVIDUAL AND POPULATION PREVENTION BENEFITS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S835 - S835, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31466-5
Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, http://dx.doi.org/10.1111/jvh.12384
Alavi M; Law M; Grebely J; Thein H-H; Amin J; Dore GJ, 2014, 'Time to hepatocellular carcinoma after notification of hepatitis B or C infection: a population-based cohort study, 1992-2007', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 921A - 922A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jacka B; Poon A; Applegate TL; Krajden M; Olmstead A; Harrigan R; Marshall BD; DeBeck K; Milloy M-J; Lamoury F; Pybus O; Lima V; Magiorkinis G; Montoya V; Montaner J; Joy J; Dore GJ; Kerr T; Wood E; Grebely J, 2014, 'Hepatitis C virus network dynamics among people who inject drugs in Vancouver, Canada', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 907A - 908A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD; Amin J; Schinkel J; Applegate TL; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Morris MD; Rice TM; Shiboski S; Bruneau J; Cox A; Dore GJ; Grebely J; Hahn JA; Kim AY; Lloyd AR; Hellard M; Maher L; McGovern BH; Prins M; Page K, 2014, 'Historical and geographical trends in hepatitis C virus (HCV) incident infection among people who inject drugs: The International Collaboration on Incident HCV and HIV Infection among PWID (InC3 Study)', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 894A - 895A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR; George J; Grebely J, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804082&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martin NK; Vickerman P; Dore GJ; Grebely J; Foster GR; Miners A; Hutchinson S; Goldberg DJ; Martin TC, 2014, 'Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 1042A - 1042A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Doyle JS; Dore GJ; Shaw D; Grebely J; Erratt A; Hellard M; Matthews G, 2014, 'HCV re-infection rates are low after long-term follow up of acute HCV infection: The Australian Trial of Acute Hepatitis C Recall study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 915A - 915A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Reddy KR; Roberts SK, 2014, 'High Efficacy of Treatment with Sofosbuvir+GS-5816 +/- Ribavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 297A - 298A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483801131&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore GJ; Razavi H; Estes C; Thompson A; Zekry A; Roberts S; Sievert W, 2014, 'POTENTIAL IMPACT OF IMPROVED TREATMENT ON DISEASE BURDEN OF CHRONIC HEPATITIS C IN AUSTRALIA', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, ENGLAND, London, pp. S210 - S210, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/S0168-8278(14)60589-4
Foster GR; Jacobson M; Dore GJ; Fried M; Manns M; Marcellin P; Poordad F; de Araujo ESA; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M, 2014, 'SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, ENGLAND, London, pp. S456 - S456, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/S0168-8278(14)61287-3
Martin NK; Devine A; Eaton JW; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P, 2014, 'MODELING THE IMPACT OF EARLY ANTIRETROVIRAL THERAPY FOR ADULTS COINFECTED WITH HIV AND HEPATITIS B OR C IN SOUTH AFRICA', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, ENGLAND, London, pp. S483 - S483, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/S0168-8278(14)61350-7
Jacka B; Applegate T; Poon AF; Harrigan R; Dore GJ; Olmstead A; DeBeck K; Milloy M-J; Lamoury F; Woods C; Brumme Z; Dobrer S; Lima VD; Montaner J; Joy J; Marshall BD; Kerr T; Wood E; Krajden M; Grebely J, 2014, 'TEMPORAL CHANGES IN HEPATITIS C VIRUS GENOTYPE 3A DISTRIBUTION AMONG PEOPLE WHO INJECT DRUGS IN VANCOUVER, CANADA', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, ENGLAND, London, pp. S324 - S325, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014, http://dx.doi.org/10.1016/S0168-8278(14)60923-5
Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate T; Dore G; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2014, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive MSM with acute HCV infection identifies two potential intervention targets for permucosally transmitted HCV in Australia', in HIV MEDICINE, WILEY-BLACKWELL, pp. 136 - 136, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000333652300418&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Bradshaw D; Lamoury F; Catlett B; Applegate TL; Mcallister J; Dore GJ; Matthews G; Danta M, 2013, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-positive men with acute HCV infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 913A - 913A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252204236&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate TL; Dore GJ; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2013, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive men who have sex with men (MSM) with acute HCV infection identifies two potential intervention targets for permucosally-transmitted HCV', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1307A - 1307A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252206224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Danta M; How-Chow D; McInnes E; Matthews G; Dore GJ, 2013, 'Growing burden of HCV-related advanced liver disease related to enhanced Fibroscan-based screening', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 956A - 957A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252204331&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Page K; McGovern BH; Grebely J; Kim AY; Evans J; Morris MD; Cox A; Rice TM; Sacks-Davis R; Hellard M; Bruneau J; Shoukry N; Maher L; Lloyd AR; Prins M; Dore GJ, 2013, 'IL28B Genotype is Associated with Jaundice and Elevated Aminotransferase Levels During Acute HCV Infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1188A - 1188A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252205376&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jacobson IM; Dore GJ; Foster GR; Fried MW; Manns MP; Marcellin P; Poordad F; Araujo ES; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M, 2013, 'Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 756A - 757A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252203288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Thompson AJ; Roberts S; Strasser S; Bollipo S; Sloss A; Wenman J; Cheng W; Angus P; Levy M; Mitchell J; Sievert W; Leggett B; Dore G; George J, 2013, 'IL28B genotype frequency in Australian patients with genotype 2/3 HCV differs from that observed in genotype 1 HCV: Interim analysis of the GUIDE study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 173 - 173, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jacobson IM; Dore GJ; Foster G; Fried MW; Radu MN; Rafalskiy VV; Moroz L; Craxiag A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, FL, Orlando, pp. S374 - S374, presented at Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), FL, Orlando, 18 May 2013 - 21 May 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000322997202152&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Matthews G; Rice T; Morris M; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns M; Hellard ME; Dore GJ, 2013, 'RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S332 - S332, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60813-2
Hajarizadeh B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Grady B; Schinkel J; Maher L; Hellard M; Lloyd AR; Prins M; Grebely J; Dore GJ, 2013, 'EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S470 - S471, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)61158-7
Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; McGovern BH; George J; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M, 2013, 'SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S189 - S189, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60463-8
Holmes JA; Bonanzinga S; Roberts SK; Sievert W; Dore GJ; McCaughan G; Crawford DH; Cheng WS; Weltman MD; Matthews G; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Thompson AJ, 2013, 'THE ASSOCIATION BETWEEN HAEMOGLOBIN DECLINE AND SVR IS INDEPENDENT OF ITPA GENOTYPE DURING PEG-INTERFERON PLUS RIBAVIRIN THERAPY FOR HCV-1: ANALYSIS FROM THE CHARIOT STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S189 - S190, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60464-X
Jacobson I; Dore GJ; Foster GR; Fried MW; Radu M; Rafalskiy VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S574 - S574, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)61424-5
Aspinall E; Grebely J; Hutchinson S; Innes H; Walter S; Amin J; Yu A; Goldberg D; Krajden M; Law M; Dore G, 2013, 'TRENDS IN MORTALITY AFTER DIAGNOSIS OF HEPATITIS C INFECTION - AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S397 - S398, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60967-8
Berg T; Shiffman ML; Zeuzem S; Berg CP; de Figueiredo-Mendes C; Dore GJ; Ferraz ML; Mendes-Correa MC; Lima MP; Parise E; Rios AMP; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F; Cheinquer H, 2013, '48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S323 - S323, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60794-1
Dore GJ; Lawitz E; Hezode C; Shafran S; Ramji A; Tatum H; Taliani G; Tran A; Brunetto M; Zaltron S; Strasser S; Weis N; Ghesquiere W; Lee S; Larrey D; Pol S; Harley H; George J; Fung S; de Ledinghen V; Hagens P; Cohen D; Cooney E; Noviello S; Hughes E, 2013, 'DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S570 - S571, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)61417-8
Kitson MT; Dore GJ; George J; Button P; McCaughan GW; Crawford DH; Sievert W; Weltman MD; Cheng WS; Roberts SK, 2013, 'INTERLEUKIN-28B rs12979860 C ALLELE IS PROTECTIVE AGAINST ADVANCED FIBROSIS IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S191 - S191, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60468-7
Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2013, 'CONTINUED LOW UPTAKE OF TREATMENT FOR HCV IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S319 - S320, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60787-4
Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'SEQUENCING THE HEPATITIS C VIRUS: A SYSTEMATIC REVIEW', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S471 - S472, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)61160-5
Dore GJ; Lawitz E; Hezode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Albert T; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey DG; Pol S; Harley H; George J; Fung S; de Ledinghen V; Hagens P; Cohen DS; Hughes EA; Cooney EL, 2012, 'Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 558A - 559A, presented at 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 09 November 2012 - 13 November 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310955602141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cheinquer H; Shiffman ML; Zeuzem S; Berg CP; Berg T; Figueiredo-Mendes CG; Dore GJ; Ferraz ML; Mendes-Correa MC; Lima MP; Parise ER; Perez AM; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F, 2012, 'The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 271A - 272A, presented at 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 09 November 2012 - 13 November 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310955601156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts S; Mitchell J; Leung RC; Booth D; Mccaughan G; Crawford DH; Thompson A; Sievert W; Dore G; George J, 2012, 'The distribution of polymorphisms in the IL28B gene in previously untreated Australian patients with genotype 1 CHC: the predict study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 178 - 178, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600361&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dore GJ; van der Loeff MS; Rice T; Cox AL; Bruneau J; Kim AY; George J; Maher L; Lloyd AR; Hellard M; Page K; Prins M, 2012, 'FEMALE SEX AND VARIATIONS IN IL28B ARE INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S348 - S348, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/S0168-8278(12)60906-4
Grebely J; Feld JJ; Applegate T; Matthews G; Hellard M; Sherker A; Petoumenos K; Shaw I; Yeung B; Kaldor JM; Cherepanov V; Bruneau J; Lloyd A; Shoukry N; Dore G, 2012, 'PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S346 - S346, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/S0168-8278(12)60901-5
Kitson MT; Dore GJ; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Roberts SK, 2012, 'VITAMIN D STATUS IS ASSOCIATED WITH COMPLETE EVR BUT NOT SVR IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S443 - S444, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/S0168-8278(12)61138-6
Kitson MT; Dore GJ; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Roberts SK, 2012, 'VITAMIN D STATUS AND LIVER HISTOLOGY IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S350 - S351, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/S0168-8278(12)60913-1
Ali RJ; Bowden S; Avihingsanon A; Lewin SR; Ruxrungtham K; Locarnini S; Sasadeusz J; Dore GJ; Matthews G, 2011, 'CHANGES IN QUANTITATIVE HBSAG AND HBEAG PREDICT HBV TREATMENT RESPONSE IN HBV/HIV COINFECTED INDIVIDUALS ON TENOFOVIR BASED HAART IN THAILAND', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1081A - 1081A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578003739&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews G; Applegate TL; Tschochner M; Plauzolles A; Mallal SA; Grebely J; Hellard M; Lloyd AR; Kaldor JM; Dore GJ; Gaudieri S, 2011, 'ULTRA DEEP SEQUENCING ANALYSIS OF TREATMENT NAIVE INDIVIDUALS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION DEMONSTRATES WIDESPREAD AMINO ACID VARIATION AT KEY PROTEASE AND POLYMERASE SITES OCCURRING AT LOW FREQUENCY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1343A - 1344A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578004555&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Fried M; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson IM; Marcellin P; Manns MP; Nikitin I; Poordad FF; Sherman M; Zeuzem S; Lenz O; Peeters M; Sekar V; De Smedt G, 2011, 'TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1429A - 1429A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578004737&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A86 - A86, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375700091&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A87 - A87, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375700092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Alavi M; Haber P; Day C; Matthews GV; van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Spelman T; Kaldor JM; Dore GJ; Hellard M, 2011, 'IMPACT OF TREATMENT ON INJECTING DRUG USE BEHAVIORS DURING RECENT HCV INFECTION: THE ATAHC STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S174 - S174, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60431-5
Feld JJ; Grebely J; Applegate T; Matthews GV; Hellard M; Suppiah V; Sherker A; Petoumenos K; Shaw I; Yeung B; Rawlinson W; Booth D; Kaldor JM; Lloyd AR; Dore GJ, 2011, 'IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S455 - S455, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61154-9
Ali RJ; Roberts SK; Ray J; Sievert W; McCaughan G; Weltman M; Crawford D; Cheng W; Rawlinson W; Thommes J; Rizkalla B; Yoshihara M; Dore GJ; Matthews GV, 2011, 'EARLY ON-TREATMENT PLASMA RIBAVIRIN CONCENTRATIONS ARE ASSOCIATED WITH ON-TREATMENT ANAEMIA AND TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S161 - S161, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60403-0
Grebely J; Matthews GV; Hellard M; Suppiah V; Petoumenos K; Applegate T; Yeung B; Rawlinson W; Feld J; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ, 2011, 'IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S524 - S524, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61330-5
Gaudieri S; Applegate T; Tshochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews G, 2011, 'SIGNATURE RESISTANCE MUTATIONS TO DIRECTLY ACTING ANTIVIRAL AGENTS OCCUR AT LOW PREVALENCE IN TREATMENT NAIVE SUBJECTS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S184 - S185, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60455-8
Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A87 - A87, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687677600071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A86 - A86, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687677600070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts SK; Ferenci P; Yoshihara M; Crawford DH; Sieverf W; McCaughan GW; Cheng W; Weltman M; Rawlinson WD; McCloud PI; Rizkalla B; Dore GJ, 2010, 'NON-SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IS SRONGLY PREDICTED BY BASELINE FACTORS AND WEEK 8 ON-TREATMENT VIRAL LOAD IN HCV GENOTYPE (GT) 1 PATIENTS: NEW INSIGHTS FROM CART ANALYSIS OF THE CHARIOT STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 801A - 802A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775601314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Fried MW; Buti M; Dore GJ; Ferenci P; Jacobson I; Marcellin P; Zeuzem S; Lenz O; Peeters M; Sekar VJ; De Smedt G, 2010, 'EFFICACY AND SAFETY OF TMC435 IN COMBINATION WITH PEGINTERFERON alpha-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 HCV PATIENTS: 24-WEEK INTERIM RESULTS FROM THE PILLAR STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 403A - 404A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775600168&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. S844 - S844, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000475844804188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60062-1
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4
Grebely J; Dore GJ; van der Loeff MS; Cox AL; Bruneau J; Kim AY; Lloyd AR; Hellard M; Page K; Prins M, 2010, 'FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S411 - S411, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)61064-1
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Iser DM; Boyd AJ; Avihingsanon A; Thompson AL; Nguyen T; Matthews G; Bowden S; Locarnini S; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 993A - 994A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001493&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
McCaughan GW; Roberts SK; Weltman M; Crawford DH; Sievert W; Cheng W; Rawlinson W; Yoshihara M; McCloud PI; Rizkalla B; Dore GJ, 2009, 'ADVANCED FIBROSIS IN GENOTYPE 1 HCV INFECTED PATIENTS RECEIVING ANTIVIRAL THERAPY IS ASSOCIATED WITH VIROLOGIC RELAPSE INDEPENDENT OF RAPID (RVR) AND EARLY (EVR) VIROLOGIC RESPONSE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1027A - 1028A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001564&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Marcellin P; Jensen DM; Roberts SK; Hadziyannis SJ; Dore GJ; Diago M; Weltman M; McCaughan GW; Cheng W; Crawford DH; Sievert W; Rawlinson W; Solsky J; Tietz A; Rizzetto M, 2009, 'PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1030A - 1031A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford DH; Cheng W; Weltman M; Rawlinson W; Rizkalla B; McCloud PI; Roberts SK, 2009, 'SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1020A - 1021A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Weltman M; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng W; Rawlinson W; Yashihara M; McCloud PI; Rizkalla B; Roberts SK, 2009, 'BASELINE AND ONTREATMENT PREDICTORS OF SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IN HCV GENOTYPE (GT) 1 TREATMENT NAIVE PATIENTS: NEW INSIGHTS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1033A - 1034A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001574&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini S; Sasadeusz J; Sievert W; Peschell KJ; Mitchell K; Elsome AM, 2009, 'PREVALENCE AND NATURE OF VIRAL MUTATIONS IN CHRONIC HEPATITIS B (CHB) PATIENTS ON ORAL ANTIVIRAL THERAPY (AVT): THE CHARM STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 488A - 489A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000390&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Iser DM; Boyd A; Avihingsanon A; Thompson AJ; Nguyen T; Matthews GV; Bowden S; Locarnini SA; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'No increase in intrahepatic mononuclear or stellate cell activation in HIV-HBV co-infected individuals', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A292 - A292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini SA; Sasadeusz JJ; Sievert W; Peschell K; Mitchell K, 2009, 'Prevalence and characteristics of hepatitis B virus (HBV) mutations in chronic hepatitis B (CHB) patients on oral antiviral therapy (AVT): the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A296 - A296, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200207&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Baleriola C; Rawlinson W; Chaverot S; Stelzer-Braid S; Yoshihara M; Rizkalla B; Dubois D; Sievert W; McCaughan G; Crawford DHG; Weltman M; Cheng WSC; Dore GJ; Roberts S, 2009, 'IMPACT OF LOW-LEVEL HEPATITIS C VIRAEMIA AT WEEK 24 ON HCV TREATMENT RESPONSE IN GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S220 - S220, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60600-0
Cheng WSC; Roberts S; Weltman M; Crawford DHG; Sievert W; McCaughan G; Rawlinson W; Desmond P; Yoshihara M; Rizkalla B; DePamphilis J; Marks P; Dore GJ, 2009, 'EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 mu G/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE I PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S221 - S221, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60603-6
Roberts S; Weltman M; Crawford DHG; Cheng WSC; Sievert W; McCaughan G; Desmond P; Rawlinson W; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'HIGH-DOSE PEGINTERFERON ALFA-2A (40KD) INDUCTION THERAPY AND STANDARD RIBAVIRIN ENHANCES EARLY BUT NOT SUSTAINED VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS: FINAL CHARIOT STUDY RESULTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S50 - S51, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60126-4
Grebely J; Raffa J; Lai C; Krajde M; Fischer B; Kerr T; Dore G; Tyndall M, 2009, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S152 - S152, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60404-9
Dalgard O; Grebely J; Dore GJ, 2009, 'Hepatitis C virus reinfection following sustained virological response in injection drug users', in Suchtmedizin in Forschung und Praxis, pp. 231 - 234
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Sasadeusz J; Dore GJ; Kronborg I; Barton DA; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 894A - 894A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401690&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini SA; Sasadeusz JJ; Sievert W; Elsome AM, 2008, 'Prevalence and nature of viral mutations in chronic hepatitis B patients on antiviral therapy: the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A264 - A264, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Jin F; Prestage G; Dore GJ; Zablotska I; Rawstorne PR; Kippax SC; Kaldor JM; Grulich AE, 2008, 'Prevalence, Incidence and Risk Factors for Hepatitis C in HIV Negative and HIV Positive Homosexual Men', in Sexual Health, CSIRO Publishing, Australia, pp. 20 - 21, presented at Sexual Health, Perth, 17 September 2008 - 20 September 2008
Crawford D; Robertson SL; Weltman MD; Cheng W; Sievert W; McCaughan G; Desmond PV; Alston A; DePamphilis J; Marks PB; Dore GJ, 2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology
Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1310 - 1311, presented at Hepatology
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology
Grebely J; Raffa J; Krajde M; Fischer B; Kerr TH; Dore GJ; Tyndall M, 2008, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. 401 - 402, presented at Journal of Hepatology
Audsley J; Littlejohn M; Yuen L; Desmond C; Dore GJ; Ruxrungtham K; Locarnini S; Thio C; Lewin S; Revill P, 2008, 'Virological characteristics of a longitudinal HIV/HBV co-infected cohort prior to initiation of HBV-active HAART', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Gidding H; Topp L; Middleton M; Dore G; Robinson K; Maher L; Kaldor J; Law M, 2008, 'The epidemiology of hepatitis C in Australia-a review of notifications, treatment uptake, and associated liver transplantations 1997-2006', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A379 - A379, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Nguyen VT; Amin J; Law MG; Dore GJ, 2008, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A343, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Hellard M; Matthews G; Petoumenos K; Grebely J; Haber PS; Van Beek IA; Marks P; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A344 - A344, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; Grebely J; White PA; Renkin M; Marks PB; Ffrench R; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology, San Francisco, CA, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757402521&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd AR; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A365 - A366, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Jones T; Marks P; Connelly C; Warner S; Fragomeli V; Walker PJ; Ferguson CM; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A241 - A241, presented at Journal of Gastroenterology and Hepatology, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
White PA; Grebely J; Flynn J; Matthews G; Renkin M; Yeung B; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Ffrench R; Dore GJ, 2008, 'NATURAL HISTORY OF HCV SUPERINFECTION AND REINFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1056 - 1057, presented at Hepatology, San Francisco, CA, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; Hellard M; Haber PS; Yeung B; Marks PB; Sasadcusz J; Baker DA; McCaughan G; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S303 - S303, presented at Journal of Hepatology, Milan, ITALY, http://dx.doi.org/10.1016/S0168-8278(08)60812-0
Matthews G; Hellard M; Haber PS; Yeung B; Marks P; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
White PA; Grebely J; Matthews G; Flynn J; Renkin M; Kaldor JM; Lloyd AR; Hellard M; Ffrench R; Dore GJ, 2008, 'Natural history of HCV reinfection and superinfection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A355 - A355, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Grebely J; Matthews G; White PA; Renkin M; Flynn J; Ffrench R; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A344, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Hellard M; Grebely J; Matthews G; Haber PS; Petoumenos K; Yeung B; Van Beek IA; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Impact of illicit drug use on response to therapy during treatment for acute and early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A338, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Thio C; Bowden SJ; Ayres A; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'Tenofovir based HAART is associated with high rates of HBV DNA suppression and HBEAG seroconversion in thai HIV-HBV coinfected patients', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A336, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Flynn J; White PA; Grebely J; Kaldor JM; Hellard M; Dore GJ; Lloyd AR; Ffrench R, 2008, 'Immunity to acute hepatitis C and the influence of early therapy', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A356 - A356, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Maher L; Dore G; Treloar C; Rawlinson W; White P; Dolan K; Zekry A; Madden A; Loveday S; Kaldor J; Lloyd A, 2008, 'Preparedness for candidate hepatitis C vaccine trials in people who inject drugs: challenges and opportunities', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A358, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600072&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Grebely J; Ngai T; Knight E; Duncan F; Raffa J; Genoway K; Showler G; Krajden M; Dore GJ; Conway B, 2008, 'Low rate of hepatitis C virus re-infection following sustained virological response among injection drug users having received treatment for HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A338 - A338, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT, 2008, 'Modeling population-based chronic hepatitis B screening and treatment to prevent cirrhosis and liver cancer among high risk populations in Australia', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A359, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600074&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Roberts S; Weltman M; Crawford D; Cheng W; Sievert W; McCaughan GW; Desmond PV; Yoshihara M; Miller JE; Depamphilis J; Marks P; Dore GJ, 2007, 'Rapid and early virological response rates are increased with 12 week 360 mu g/wk peginterferon alfa-2A (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: Efficacy and safety analysis of the induction phase of the CHARIOT study', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 257A - 258A, presented at 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 02 November 2007 - 06 November 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249910400055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts S; Cooksley G; Dore G; Robson R; Shaw D; Berns H; Brandt M; Fenner S; Hill G; Ipe D; Klumpp K; Mannino M; O'mara E; Najera I; Tu Y; Washington C, 2007, 'Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. A779 - A779, presented at Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting, DC, Washington, 19 May 2007 - 24 May 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000245927606317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Klumpp K; Smith D; Brandl M; Alfredson T; Sarma K; Smith M; Najera I; Jiang W-R; Le Pogam S; Leveque V; Ma H; Tu Y; Chan R; Chen C-W; Wu X; Birudaraj R; Swallow S; Martin JA; Cammack N; Berns H; Fettner S; Ipe D; Mannino M; O'Mara E; Washington C; Roberts S; Cooksley G; Dore G; Shaw D; Blue DR; Zahm F; Hill G, 2007, 'Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability', in ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV, CA, Palm Spring, pp. A35 - A35, presented at 20th International Conference on Antiviral Research, CA, Palm Spring, 29 April 2007 - 03 May 2007, http://dx.doi.org/10.1016/j.antiviral.2007.01.029
McCaughan GW; Omata M; Amarapurkar D; Bowden S; Chow WC; Chutaputti A; Dore G; Gane E; Guan R; Hamid SS; Hardikar W; Hui CK; Jafri W; Jia JD; Lai MY; Wei L; Leung N; Piratvisuth T; Sarin S; Sollano J; Tateishi R, 2007, 'Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection', in Journal of Gastroenterology and Hepatology (Australia), pp. 615 - 633, http://dx.doi.org/10.1111/j.1440-1746.2007.04883.x
Campbell S; Norris S; Mernagh P; Batey R; Dore GJ, 2006, 'Economic modelling to determine the cost-effectiveness of treatment of patients with histologically mild chronic hepatitis C with pegylated interferon alpha-2b plus ribavirin', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, pp. A307 - A307, http://dx.doi.org/10.1016/S1098-3015(10)63528-0
Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2006, 'Estimates of Hepatitis B-Realted Liver Cancer Among Vietnam Born Population in Australia', in 18th Annual ASHM Conference, 18th Annual ASHM Conference, Melbourne, pp. 152 - 153, presented at 18th Annual ASHM Conference, Melbourne, 11 October 2006 - 14 October 2006
Hellard M; Dore G; Haber P; Marks P; Matthews G; Yeung B; Nguyen O; Pan Y; Ffrench R; McCaughan G; Van Beek I; White P; Dolan K; Rawlinson W; Lloyd A; Kaldor J, 2006, 'Australian trial in acute hepatitis C: preliminary findings', in JOURNAL OF CLINICAL VIROLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S139 - S139, presented at 12th International Symposium on Viral Hepatitis and Liver Disease, FRANCE, Paris, 01 July 2006 - 05 July 2006, http://dx.doi.org/10.1016/S1386-6532(06)80430-0
Nguyen VT, 2006, 'Highly endemic Hepatitis B infection in Rural Vietnam', in Shanghai - Hong Kong International Liver Congress 2006, Shanghai, pp. 2093 - 2100, presented at Shanghai - Hong Kong International Liver Congress 2006, Shanghai, 25 March 2006 - 28 March 2006, http://dx.doi.org/10.1111/j.1440-1746.2007.05010.x
Nguyen VT; McLaws M; Dore GJ, 2006, 'Highly endemic hepatitis B infection in rural Vietnam', in Hepatitis 5th Australian Conference, Hepatitis 5th Australian Conference, Sydney, pp. 20 - 22, presented at Hepatitis 5th Australian Conference, Sydney, 20 February 2006 - 22 February 2006
Ffrench RA; Flynn J; Goy K; Hosseiny P; Pan Y; Rawlinson WD; White PA; Nguyen O; Hellard M; Kaldor JM; Dore GJ; Lloyd AR, 2006, 'Comprehensive analysis of IFN-gamma and IL-2 production by T cells in acute and chronic HCV infection', in Journal of Clinical Virology, Elsevier Science BV, Amsterdam, Netherlands, pp. S123 - S123, presented at Journal of Clinical Virology, Melbourne, http://dx.doi.org/10.1016/S1386-6532(06)80380-X
Nguyen VT; McLaws M; Dore GJ, 2006, 'Highly endemic hepatitis B infection in rural Vietnam', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A98 - A98, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000247320400077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Amin J; Law MG; Bartlett M; Kaldor JM; Dore GJ, 2005, 'Causes of death in people with hepatitis B or C infection: A population based cohort study', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 214A - 214A, presented at 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 11 November 2005 - 15 November 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000232480300046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hardikar W; Polis S; Kesson A; Mews C; Jones C; Elliott E; Dore G; Kaldor J, 2004, 'National surveillance of hepatitis C virus infection in Australian children.', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 415A - 415A, presented at 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 29 October 2004 - 02 November 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000224102100578&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Freeman AJ; Law MG; Kaldor JM; Dore GJ, 2002, 'Hepatitis C: The Australian experience.', in HEPATOLOGY, W B SAUNDERS CO, MASSACHUSETTS, BOSTON, pp. 554A - 554A, presented at 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), MASSACHUSETTS, BOSTON, 01 November 2002 - 05 November 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178301701545&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Wettstein AR; Maddocks S; Dore G; Edwards P, 1999, 'Association of cryptosporidiosis to HIV-related cholangiopathy and the role of protease inhibitors', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. A39 - A39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000079778400165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Wettstein A; Dore G; Murphy C; Hing M; Edwards P, 1997, 'HIV-related cholangiopathy in Australia', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. A1117 - A1117, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WV41904452&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham E; Estes C; Razavi H; Gray RT, 2018, 'Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake', presented at International Liver Congress (European Association for the Study of the Liver (EASL 2018)), 11 April 2018 - 15 April 2018
Cunningham EB; Hajarizadeh B; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Bretana NA; Dolan K; Lloyd AR; Grebely J, 2018, 'A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING', in Journal of the Canadian Association of Gastroenterology, Oxford University Press (OUP), Vol. 1, pp. 278 - 280, http://dx.doi.org/10.1093/jcag/gwy008.162
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Homie R; Gray RT, 2018, 'Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up', presented at Australasian Viral Hepatitis Conference, 13 August 2018 - 15 August 2018
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'Australia Could Meet the WHO HCV Elimination Targets If the Current Rollout of DAA Treatment Is Continued', presented at Australasian Viral Hepatitis Conference (AVHC), 10 August 2017 - 11 August 2017
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S12 - S12, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30286-6
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S291 - S292, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30899-1
Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I; Lagios K; Grebely J; Lloyd A, 2017, 'A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S495, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31387-9
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 886A - 886A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 948A - 948A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G; Swan T; Backmund M; Marks P; Grebely J; Dore GJ; Applegate TL, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S625 - S626, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6
Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J; Marks P; Quiene S; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Bourgeois S; Thurnheer C; Dore GJ, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3
Alavi M; Valerio H; Law M; Lockart I; Danta M; Grebely J; Amin J; Hajarizadeh B; George J; Dore G, 2022, 'Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S568 - S569, http://dx.doi.org/10.1016/s0168-8278(22)01458-1
Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Innes H; Dore G, 2022, 'Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S560 - S560, http://dx.doi.org/10.1016/s0168-8278(22)01443-x
Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Dore G, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S302 - S302, http://dx.doi.org/10.1016/s0168-8278(22)00971-0
Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9
Lockart I; Hin Yeo MG; Hajarizadeh B; Dore G; Danta M, 2022, 'Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S561 - S562, http://dx.doi.org/10.1016/s0168-8278(22)01445-3
Price O; Dietze PM; Maher L; Dore GJ; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena U; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'COVID-19 VACCINE HESITANCY AMONG AUSTRALIANS WHO USE DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S120 - S120, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200293&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'OVERVIEW AND FINDINGS OF THE COLAB STUDY: AN OPEN-LABEL IMPLEMENTATION STUDY OF SUBLOCADE TREATMENT IN SPECIALIST AND PRIMARY CARE SETTINGS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S25 - S25, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM TRIAL OF MONTHLY INJECTIONS OF EXTENDED RELEASE BUPRENORPHINE IN PEOPLE WITH OPIOID USE DISORDER: THE COLAB STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S71 - S72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lockart I; Yeo M; Hajarizadeh B; Dore GJ; Danta M, 2021, 'Hepatocellular carcinoma occurrence after hepatitis C virus cure among patients with advanced fibrosis or cirrhosis: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 36, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693377800070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Alavi M; Hajarizadeh B; Grebely J; Law M; Amin J; George J; Danta M; Dore G, 2021, 'comparison of hbv-related hcc incidence between entecavir and tenofovir treated cohorts: a population-based study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S515 - S516, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000667753801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lazarus J; Picchio C; Byrne C; Crespo J; Colombo M; Cooke G; Dore G; Grebely J; Ward J; White T; Dillon J, 2021, 'A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S661 - S662, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000667753801295&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hosseini-Hooshyar S; Alavi M; Martinello M; Matthews G; Dore G, 2021, 'Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 24, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713652900036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lockart I; Hajarizadeh B; Alavi M; Davison S; Section EP; Levy MT; George J; Dore GJ; Danta M, 2020, 'Sustained virological response before hepatitis C-related hepatocellular carcinoma diagnosis is associated with improved survival', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 35, pp. 53 - 54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000589476200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon JA; Dore G; Hajarizadeh B; Guy R; Gray RT, 2020, 'Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 73, pp. S606 - S606, http://dx.doi.org/10.1016/s0168-8278(20)31680-9
He S; Dore G; Law M; Heahter V; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'IMPROVED SURVIVAL FOLLOWING HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE DIRECT-ACTING ANTIVIRAL THERAPY ERA IN NEW SOUTH WALES, AUSTRALIA', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 906A - 906A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503195&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Conway B; Litwin AH; Dalgard O; Shibolet O; Nahass RG; Altice F; Gane EJ; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Kelly M; Hwang P; Asante-Appiah E; Barr E; Robertson MN; Platt H; Dore G, 2019, 'DRUG USE AND REINFECTION DURING AND FOLLOWING HCV TREATMENT WITH ELBASVIR/GRAZOPREVIR AMONG PATIENTS RECEIVING OPIOID AGONIST THERAPY: FINAL RESULTS FROM THE CO-STAR STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 955A - 956A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500824000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kearley J; Gilliver R; Lothian R; Cunningham EB; Dore GJ; Read P, 2019, 'MAXIMISING ADHERENCE TO DIRECT-ACTING ANTI-VIRALS FOR HEPATITIS C AMONG STREET-BASED AND MARGINALISED CLIENTS USING AN OPIOID AGONIST TREATMENT PROGRAM: THE RESULTS OF DAILY DOSING', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kearley J; Gilliver R; Lothian R; Dore GJ; Read P, 2019, 'WHEN TREATMENT ACCESS DOES NOT EQUAL TREATMENT INITIATION: AN ANALYSIS OF CLIENTS WHO DO NOT INITIATE DIRECT ACTING ANTIVIRALS FOR HEPATITIS C', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S60 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Marshall AD; Grebely J; Dore GJ; Treloar C; Corry A; Hayllar J; Byrne J, 2019, 'SYMPOSIUM: ENHANCING HEPATITIS C CARE AMONG PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S8 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Dore G; Law M; Valerio H; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'Improved survival after hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 82 - 82, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Hajarizadeh B; Lockart I; Alavi M; Danta M; Dore G, 2019, 'Effectiveness of direct-acting antiviral therapy for hepatitis C among people with hepatocellular carcinoma: A systematic review and meta-analysis', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 71 - 72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Valerio H; Alavi M; Silk D; Treloar C; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Degenhardt L; Dore G; Grebely J, 2019, 'Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E42 - E42, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, http://dx.doi.org/10.1016/S0618-8278(19)30076-3
Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthew G, 2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Altice F; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Huang H-C; Kelly MM; Hwang P; Barr E; Robertson MN; Platt H; Dore G, 2018, 'HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B', in HEPATOLOGY, WILEY, CA, San Francisco, Vol. 68, pp. 35A - 35A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, CA, San Francisco, 09 November 2018 - 13 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000446020500053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Salazar-Vizcaya L; Boettiger DC; Dore GJ; Gray R; Law M; Rauch A; Lea T; Matthews G, 2018, 'Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia?', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 21, pp. 66 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440002700139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J; Montebello M; Collie P; Hallinan R; Cooper L; Marks P; Hajarizadeh B; Matthews GV, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dore G; Hezode C; Kwo P; Sperl J; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 56 - 57, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dalgard O; Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Soyemi T; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hcv in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 13 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018
Hezode C; Kwo P; Sperl J; Dore G; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, Vol. 68, pp. S264 - S265, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461068601134&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Foster GR; Grebely J; Sherman KE; Wang S; Dore GJ; Baumgarten A; Conway B; Jackson DF; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar HI; Alami NN; Dumas EO; Hu Y; Mensa FJ, 2017, 'Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 636A - 637A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801215&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Marshall AD; Nielsen S; Cunningham EB; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Flisiak R; Foster G; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancoriene L; Jarcuska P; Kaberg M; Makara M; Maimets M; Marinho R; Maticic M; Norris S; Olafsson S; Ovrehus A; Pawlotsky J-M; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2017, 'Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S95 - S96, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30450-6
Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Foster GR; Gane E; Asatryan A; Asselah T; Ruane PJ; Pol S; Poordad F; Stedman CA; Dore G; Roberts SK; Kaita K; Vierling J; Vargas HE; Kort J; Lin C-W; Liu R; Ng T; Mensa F, 2017, 'ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S33 - S33, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30326-4
Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe A; Miller V; Bull RA; Ceccherini-Silberstein F; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky J-M; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S323 - S323, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30970-4
Lamoury FM; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty GA; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S710 - S710, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31901-3
Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5
Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly MM; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2016, 'HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 431A - 431A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500109&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Larney S; Grebely J; Degenhardt L; Amin J; Law M; Alavi M; Dore GJ, 2016, 'EXPOSURE TO OPIOID SUBSTITUTION THERAPY FOLLOWING HEPATITIS C NOTIFICATION: IMPLICATIONS FOR PROVISION OF ANTIVIRAL THERAPIES IN DRUG TREATMENT SETTINGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Mauss S; Brown A; Bronowicki J-P; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION RECEIVING OPIOID SUBSTITUTION THERAPY: PHASE 3 ION TRAILS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Alavi M; Janjua N; Yu A; Grebely J; Aspinall E; Innes H; Valerio H; Hayes P; Krajden M; Amin J; Law M; George J; Goldberg D; Hutchinson S; Dore G, 2016, 'DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S462 - S463, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00776-5
Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1
Conway B; Luo Y; Arama V; Ghesquiere W; Sasadeusz J; Skoien R; Soza A; Inglot M; Sullivan D; Podsadecki T; Dore G, 2015, 'Ombitasvir/Paritaprevir/r and Dasabuvir plus /- Ribavirin is Better Tolerated Than Telaprevir plus Peginterferon/Ribavirin With Less Frequent and Less Severe Anemia in the MALACHITE-I and MALACHITE-II Trials', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 782A - 783A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375402483&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Zeuzem S; Mizokami M; Pianko S; Mangia A; Han K-H; Martin R; Svarovskaia ES; Dvory-Sobol H; Doehle B; Pang PS; Knox SJ; McHutchison JG; Brainard DM; Miller MD; Mo H; Chuang W-L; Jacobson IM; Dore G; Sulkowski MS, 2015, 'Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 254A - 255A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375400092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Janjua NZ; Yu A; Kuo ME; Alavi M; Woods R; Alvarez M; Dore G; Tyndall M; Krajden M, 2015, 'Timing of Hepatitis B and C Diagnosis Relative to Hepatocellular Carcinoma Diagnosis in the BC Hepatitis Testers Cohort (BC-HTC)', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 480A - 480A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375401426&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Alavi M; Grebely J; Micallef M; Dunlop A; Balcomb A; Day C; Treloar C; Bath N; Haber P; Dore G, 2015, 'TREATMENT FOR HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS IN THE OPIOID SUBSTITUTION SETTING: THE ETHOS STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, Vol. 62, pp. S673 - S673, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31085-0
Dore GJ, 2013, 'MOVING THE AGENDA FORWARD: ENHANCING HCV TREATMENT UPTAKE AND OUTCOMES FOR PEOPLE WITH DRUG DEPENDENCY', in DRUG AND ALCOHOL REVIEW, WILEY-BLACKWELL, Vol. 32, pp. 2 - 3, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326649400006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Micallef JM; Jauncey M; Amin J; Rawlinson W; Gilmour S; van Beek I; Kaldor JM; White PA; Dore GJ, 2003, 'Hepatitis C virus reinfection within a cohort of injecting drug users.', in HEPATOLOGY, W B SAUNDERS CO, MASSACHUSETTS, BOSTON, Vol. 38, pp. 266A - 266A, presented at 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, MASSACHUSETTS, BOSTON, 24 October 2003 - 28 October 2003, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000185816700230&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney
Wilson D; Kwon A; Anderson J; Thein H; Law M; Maher L; Dore G; Kaldor J, 2009, Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs among injecting drug users in Australia, Publications Production Unit (Public Affairs, Parliamentary and Access Branch) Commonwealth Department of Health and Ageing, Canberra, Australia, 3123, http://www.nchecr.unsw.edu.au/nchecrweb.nsf/resources/Reports/$file/RO-2ReportLQ.pdf
Bartlett SR, 2017, Molecular epidemiology of recently acquired hepatitis C virus infection in Australia
Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, 2022, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248
Cysique L; Jakabek D; Bracken S; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley D; Byrne A; Phetsouphanh C; Kelleher A; Dore G; Matthews G; Guillemin G; Brew B, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, http://dx.doi.org/10.1101/2022.06.07.22276020
Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824
Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670
Joseph S; Dore GJ, Vaccine Apartheid: A Human Rights Analysis of COVID-19 Vaccine Inequity, http://dx.doi.org/10.2139/ssrn.3876848
Lockhart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M, Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis, http://dx.doi.org/10.2139/ssrn.3950271
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916
Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, http://dx.doi.org/10.1016/j.jhep.2017.03.035
Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, http://dx.doi.org/10.1016/j.jhep.2016.12.028
